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A B S T R A C T
Oxidative stress is the product or aetiology of various multifactorial diseases; on the other hand, the develop-
ment of multifunctional compounds is a recognized strategy for the control of complex diseases. To this end, a
series of benzothiazole derivatives was synthesized and evaluated for their multifunctional effectiveness as
antioxidant, sunscreen (filter), antifungal and antiproliferative agents. Compounds were easily synthesized via
condensation reaction between 2-aminothiophenols and different benzaldehydes. SAR study, particularly in
position 2 and 6 of benzothiazoles, led to the identification of 4g and 4k as very interesting potential compounds
for the design of multifunctional drugs. In particular, compound 4g is the best blocker of hERG potassium
channels expressed in HEK 293 cells exhibiting 60.32% inhibition with IC50 = 4.79 μM.
1. Introduction
Multifactorial diseases, such as cancer, are caused by a combination
of genetic and/or environmental factors and have complex pathological
mechanisms. However, it is not always easy to find drugs that can act
on different sites. Several approaches, including cocktails of drugs, were
developed for the extension of prevention and effective therapy, as well
as reduction of the disease complications. Nevertheless, these meth-
odologies were found to be inefficient due to their complex side effects
and the unbalance between pharmacokinetic and pharmacodynamic
relationships. Nowadays a new approach to the problem consists in the
design and development of a single multifunctional chemical entity
[1,2] (see Fig. 1).
Environmental factors that can cause multifactorial diseases include
exposure to ultraviolet radiation (UVR) or other forms of radiation (e.g.
X-rays, gamma rays), pollution and related chemical substance, viruses,
bacterial and fungal infections, diet and lifestyle. UV radiation (UVB
and UVA) can damage cellular components (DNA, RNA, proteins, lipids,
trans-urocanic acid and aromatic amino acids) contributing to the de-
velopment of various skin diseases, including photoaging (accelerated
skin and eyes aging) and cancer [3–5]. Furthermore, absorption of UVB
by DNA bases induces the formation of cyclobutane pyrimidine dimers
(CPDs) and pyrimidine-pyrimidone (6–4) photoproducts (6–4PPs)
[6,7], while absorption of UVA induces the formation of photo-excited
states of chromophores, generating reactive species that damage DNA
[8]. Thus, UVA is a potent inducer of a variety of physiological changes
characteristic of photoaging including chronic inflammation, im-
munosuppression and cancer [9]. In general, UV damage are also as-
sociated to ROS (reactive oxygen species) production, they are highly
unstable and reactive molecules and for this reason they are read-
ily detoxified or neutralized by biological system (enzymatic and non-
enzymatic antioxidant). When ROS increase, the antioxidant defences
could not be enough to neutralize the free-radical production inducing
the oxidative stress. ROS react with lipids, nucleic acids and proteins,
altering their cellular functions and contributing to many diseases.
Mycotoxins are very toxic for human and animal cells. Low mole-
cular weight mycotoxins are soluble in lipids and can penetrate into
skin creating damage to the cells, resulting specifically aflatoxin, car-
cinogenic to mankind. In addition, chronic aflatoxicosis lead to cancer
and immune suppression [10]. Cells treated with mycotoxins (i.e.
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ochratoxin A (OTA) and/or aflatoxin B1 (AFB1) produces high level of
ROS and the use of antioxidant agents have shown to be effective in
contrasting their cytotoxicity [11].
Therefore, it is important to develop products with the ability to
prevent or inhibit the harmful effects of environmental factors de-
scribed above.
PBSA (2-phenyl-1-H-benzimidazole-5-sulfonic acid) is a hetero-
cyclic sunscreen filter used in the last 20 years in commercial products
without any particular drawbacks. It is water-soluble, protects against
UVB rays and has a good safety profile. Based on these properties, we
recently selected PBSA as a model molecule for sequential modification
to obtain potential new sunscreen filters endowed also with other
biological properties useful in skin disorders treatment. Completely
unattended, the new molecules resulted very potent radical scavenger
(useful to counteract UV radiation effects) also endowed with an in-
teresting UV-filter boosting activity when used in combination with
conventional UV-sunscreen filters [12].
Inspired by this results, continuing our search for scaffolds for novel
multi-active compounds with a good profile of safety, and also to fur-
ther investigate the above observed effects, we turned our attention to
benzothiazoles that are very well represented in several class of drugs
such as anti-diabetic [13], Alzheimer [14], antimicrobial [15–21], an-
thelmintic, anticancer [22–30], analgesic [31,32], anticonvulsant
[33–36], trypanocidal [37], antifungal, neuroprotective [35], anti in-
flammatory [32] and microsomal triglyceride transfer protein (MTP)
inhibitors activity [38]. In addition, among the whole class, 2-aryl
benzothiazole is the most investigated due to its wide range of syn-
thetic, industrial and pharmaceutical application as amyloid imagining
agents [39], schistosomicidial [18], antioxidant, anticancer agents
[40].
On the other hand, phenolic compounds are most reactive and im-
portant class of natural compounds, because of their biological and
pharmacological properties, especially antioxidant activity by H-atom
donation or electron transfer [41,42]. Considering that benzothiazoles
and phenols exhibit multiple pharmacological properties, including
antioxidant effects and skin protection from UVR, their molecular
combination could be interesting for the research of new multi-
functional compounds.
Taking into consideration the results obtained by us with benzimi-
dazole polyphenols [12], this work focused on the design and synthesis
of a series of 2-arylbenzothiazole derivatives which are also isosters of
benzimidazole.
By exploiting the structure-activity relationship, an extended in-
vestigation on 2-arylbenzothiazole derivatives was developed main-
taining the same auxochrome at position 2 and inserting substitutions
at the position 6. At this position, we have a proton (-H), a carboxylic
acid (-COOH) and a sulfonamide (-SO2NH2), these latter are both non-
classic isosteres.
2-Phenylbenzothiazole (4a) was chosen as reference compound in
all the tests performed as it represented the unsubstituted parent
compound.
To better discuss the structure-activity relationship, the ten series
shown here include both newly synthesized and already known com-
pounds. In order to explore the possibility of a multi-target approach,
all synthesized compounds were evaluated for their photoprotective,
antioxidant, antifungal and antiproliferative activities.
2. Results and discussion
2.1. Chemistry
In the literature several methods of synthesis of benzothiazoles had
been reported such as the condensation of 2-aminothiophenol with
substituted nitriles, carboxylic acids, aldehydes, acyl chlorides or esters
[43]. After evaluating these methods, we finally turned our attention to
simple and effective procedure which involves condensation of 2-ami-
nothiophenol with aldehydes using sodium hydrosulfite as oxidizing
agent. Compounds 4b, 4e, and 4f have been also synthesized under free
catalyst conditions.
2-Arylbenzothiazoles unsubstituted on the benzothiazole ring (4a-
k) were synthesized in one-step via condensation of 2-aminothiophenol
(1) and benzaldehydes (2a-k) in ethanol and sodium hydrosulfite as
catalyst (Scheme 1). The same reaction, without catalyst, gave a mix-
ture of benzothiazolines (3a-k) and benzothiazoles (4a-k). Therefore,
oxidation of the intermediates 3a-k was accelerated by Na2S2O4.
However, the synthesis of 2,6-disubstituted benzothiazole involved
several steps. The initial step was the preparation of intermediates 4-
amino-3-mercaptobenzoic acid hydrochloride (7) and bis(2-amino-4-
benzenesulfonamide)disulfide (10) according to a modified literature
method [44]. Treatment of 4-aminobenzoic acid with potassium thio-
cyanate in the presence of bromine in acidic condition at low tem-
perature (0–5 °C) gave 2-aminobenzothiazole-5-carbocylic acid
Fig. 1. Chemical structure of parent compound (4a).
Scheme 1. Synthetic route of compounds 4a-k. Reagents and conditions: (a) EtOH, Na2S2O4 in H2O, Reflux.
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hydrochloride (6) which was converted into 7 by alkaline hydrolysis
(Scheme 2).
To optimize the synthetic condition for 2-aminobenzothiazole-6-
sulfonamide, two solvents were tried: acetic acid and methanol. Acetic
acid was found to be the most suitable reaction media giving a high
reaction rate and good yield of the product. Treatment of 2-amino-
benzothiazole-6-sulfonamide with aqueous potassium hydroxide gave
bis(2-amino-4-benzenesulfonamide)disulfide (Scheme 3). Therefore,
the thiazole ring was opened but the sulfonamide group did not hy-
drolyze to a sulfonate.
Subsequently, condensation of 7 or 10 with benzaldehydes (2b-k)
yielded to the corresponding benzothiazole compounds (11b-v), sum-
marized in Scheme 4. All reactions were conducted in ethanol with
catalyst to evaluate the efficiency of sodium hydrosulfite. For all com-
pounds, the best results were obtained in the presence of catalyst.
However, among reactions without catalyst, those with bis(2-amino-4-
benzenesulfonamide) disulfide gave corresponding 2-ar-
ylbenzothiazoles with good yield whereas reaction with 4-amino-3-
mercaptobenzoic acid gave the desired product with yield less than
30%.
To better analyze the experimental results, the compounds were
divided into ten classes (A-J), which differ from the parent compound
for the substitutions on the 2-aryl ring (Table S1). In each class, the
compounds present the same substitution on the 2-aryl ring while the
substituent at 6 position of the benzothiazole ring change.
2.2. Biological evaluations
2.2.1. Photoprotective activity
Since the Sun Protection Factor (SPF) is related to the UV absorption
of the substances, the spectral profile of the synthesized compounds was
examined in the first part of this study. Absorption spectra were mea-
sured from 290 to 400 nm. The wavelength of maximum absorption
(λmax) was closely related to stereo electronic effects, which can be
affected by substituents on the 2-aryl or benzothiazole moiety that alter
the electron density of compounds. The spectral absorption data of the
non-substituted molecules in position 6, dissolved in DMSO, are shown
in Fig. 2. The maximum wavelength of 4d was red-shifted relative to 4c
and can be attributed to the presence of –OH group in para position,
which lead the resonance interaction of lone pair of oxygen and π,
cloud of 2-aryl and benzothiazole group. This shift increase if -OH is at
ortho position (4b), due to the presence of the formation of an in-
tramolecular hydrogen bond between nitrogen of benzothiazole and the
hydrogen of hydroxy group. Nevertheless, substitution of the para-OH
(4d) with a para-methoxy (4e) does not have significant changes in
absorption spectra.
Indeed the absorption spectrum of 4c is similar to that of 2-ar-
ylbenzothiazole (4a). This can be explained by the fact that lone elec-
tron pair of -OH group in meta position would be delocalized on the 2-
aryl ring rather than on the whole entire molecule and, therefore, it has
very little effect on the absorption spectrum. However, λmax of 4j is
slightly higher than that of 4c since both meta positions are occupied,
Scheme 2. Synthetic route of 4-amino-3-mercaptobenzoic acid hydrochloride. Reagents and conditions: (a) MeOH, KSCN, Br2, −5°C, HCl; (b) KOH, Reflux, 35% HCl.
Scheme 3. Synthetic route of bis(2-amino-4-benzenesulfonamide)disulfide. Reagents and conditions: (a) AcOH, KSCN, Br2 in AcOH, −5°C, 30% NH3; (b) KOH,
Reflux, 35% HCl.
Scheme 4. Synthesis of compounds 11b-v. Reagents and conditions: (i) EtOH, Na2S2O4 in H2O, Reflux.
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as confirmed by Joykrishna Dey and al. [45] which demonstrated that
red-shift is observed when the number of auxochromic groups increase.
The same result is obtained with 4h, 4i, and 4g analogues of 4d, 4e, and
4b respectively, with the second -OH in meta position. The presence of
three -OH on the 2-aryl moiety (4k) makes the molecule more rigid and
promotes the shift at the longest wavelength absorption band compared
to the other compounds. Although 4g has only two hydroxyl groups, its
spectrum is similar to that of 4k, in line with the above mentioned. The
presence of an OH in position para has less influence on the shift
compared to the other position.
Substitution with an electron withdrawing group (-COOH and
-SO2NH2) at the position 6 of the benzothiazole moiety showed a ba-
tochromic shift (Figs. S1 and S2). This long wavelength absorption band
is associated with the intramolecular charge transfer transition due to
the transfer of the charge between the electron donor group (phenolic
group) to the electron-withdrawing of benzothiazole and neighboring
carboxylic or sulfonamidic chromophore. The order of λmax along the
series is -H ≪ -SO2NH2 < –COOH. Therefore absorption range increase
with the trend of the increasing electron-withdrawing ability: this could
be mainly due to the significant stabilization of the LUMO leading to a
smaller HOMO-LUMO energy space.
In short, beyond the position and the number of -OH on the 2-aryl
ring, the presence of an electron-acceptor group at the 6 position of
benzothiazole ring, as well as the extent of conjugation, favors the
bathochromic shift of the molecule absorption.
Among the proposed in vitro methods for the calculation of SPF sun
protection, two are the principal: measurement of absorption or the
transmission of UV radiation of a thin film of sunscreen agent on the
quartz plate or biomimetic membranes and spectrophotometric assay of
dilute solutions of sunscreen agent [46–48]. In order to study the syn-
thesized compounds more deeply, both methods were employed. First
of all, a pre-screening test was carried out by determination of ab-
sorption characteristics of all selected compounds dissolved in DMSO.
Then, more promising compounds were introduced in formulation (O/
W emulsion) and their transmission spectrum were determined using
polymethylmethacrylate (PMMA) plate in order to simulate real human
use [49].
2.2.1.1. In vitro studies of dilute solutions of target compounds by
spectrophotometry. The photoprotective activity is shown in Table 1.
Spectral data of samples were collected in the 290–400 nm range and
the data were elaborated by the calculator software [50]. The software
consent to evaluate COLIPA (The European Cosmetic and Perfumery
Association) – SPF, COLIPA – UVA-PF, critical wavelength value (λc)
(see Eq. (3), Eq. (4) and Eq. (5)) and UVA/UVB ratio as preliminary
theoretical data.
All the synthesized compounds, in general, showed a significant
photoprotective activity as compared to photoprotective activity of the
lead compound PBSA. Photoprotective activity of the sunscreen against
UVB is reported as SPF value. Thereby, among all classes of compounds
having a single substituent on the 2-aryl ring, those without substituent
at the 6-position of the benzothiazole moiety exhibited good photo-
protective profile, followed by compounds having -SO2NH2, and finally
compounds having -COOH. Only in class D, compound bearing -COOH
showed the best SPF value.
Moreover, it was evident that the substitution of benzothiazole ring
by COOH and SO2NH2 had no significant effect on sun protection.
Taking all together, we can summarize that the presence of a hydrogen
atom in 6 position of benzothiazole ring increases SPF value, therefore
the SAR order was -H > -SO2NH2 > -COOH. On the contrary, among
the compounds having more than one substituent on the 2-aryl ring,
those bearing -COOH group showed the best UVB profile except the
compound 11f. However, the order of SPF values according to the
substitution on the 2-aryl ring was the following: para > meta >
ortho for compounds having -H or -SO2NH2 at 6 position of ben-
zothiazole moiety, while compounds with -COOH gave the following
order: ortho > meta > para. Compounds of class B (para-methoxy
substituted on the 2-aryl ring) showed lower value than compounds of
class A, indicating that para-hydroxy group is better than para-methoxy
one, except compound 11d which showed SPF value slightly lower than
that of 11e.
The introduction of an -OH in position ortho or meta of compounds
of class A to obtain compounds of classes E and F respectively, yield to a
decrease of SPF values. In the same way, introduction of -OH in meta
nm.





















Fig. 2. Spectral profile of benzothiazole derivatives 4a-k.
Table 1
Values of SPF, UVA-PF, UVA/UVB and λc in DMSO. Each value is the mean of
three independent measurements (mean ± SEM).
Classes Compound SPF UVA-PF UVA/UVB λc (nm)
PBSA 3.40 ± 0.17 1.03 ± 0.08 0.29 322
4a 8.38 ± 0.29 0.13 ± 0.01 1.8 331
4d 21.86 ± 2.06 1.57 ± 0.02 0.81 353
A 11d 6.19 ± 0.98 2.23 ± 0.08 0.81 353
11o 19.41 ± 1.75 2.35 ± 0.10 0.32 350
4e 14.23 ± 1.43 1.30 ± 0.04 0.1 335
B 11e 6.54 ± 0.87 1.88 ± 0.12 0.65 349
11p 8.91 ± 0.45 1.80 ± 0.09 0.45 347
4c 10.05 ± 0.11 1.18 ± 0.07 0.13 335
C 11c 8.84 ± 0.64 1.71 ± 0.02 0.36 346
11n 9.42 ± 0.06 1.46 ± 0.05 0.18 340
4b 7.56 ± 0.59 2.57 ± 0.06 0.86 355
D 11b 18.03 ± 1.15 4.09 ± 0.14 0.62 358
11 m 6.59 ± 0.83 3.45 ± 0.22 0.77 360
4f 6.62 ± 0.07 3.34 ± 0.13 1.62 356
E 11f 3.43 ± 0.49 4.62 ± 0.05 1.61 370
11q 3.85 ± 0.31 4.41 ± 0.11 1.63 364
4h 5.51 ± 0.96 2.33 ± 0.16 0.9 358
F 11h 7.42 ± 0.13 7.35 ± 0.41 1.74 367
11s 5.39 ± 0.09 4.71 ± 0.08 1.40 365
4i 9,13 ± 0.34 5.94 ± 0.15 0.42 350
G 11i 17.33 ± 1.45 5.95 ± 0.26 1.02 361
11t 11.87 ± 0.07 5.80 ± 0.33 0.96 380
4g 2.82 ± 0.49 2.50 ± 0.17 0.66 381
H 11g 7.34 ± 0.49 3.32 ± 0.24 0.40 384
11r 5.47 ± 0.07 2.76 ± 0.01 0.40 382
4j 3.38 ± 0.16 1.52 ± 0.09 0.45 345
I 11j 4.45 ± 0.23 1.57 ± 0.07 0.45 353
11u 3.06 ± 0.06 1.72 ± 0.02 0.95 380
4k 3.87 ± 0.012 4.71 ± 0.08 0.86 385
J 11k 5.16 ± 0.33 7.50 ± 0.42 1.25 389
11v 3.65 ± 0.15 4.20 ± 0.19 1.34 384
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position of compounds of class D (ortho-OH) and class C (meta-OH)
gave respectively compounds of classes H (two -OH in position 2 and 5)
and I (two -OH in position 3 and 5) with lower SPF. Interestingly,
compounds of class J with three -OH on the 2-aryl ring showed SPF
values similar to those with two -OH. This means that the SPF factor not
only depends on the number of -OH on the 2-aryl ring but also on their
position. Interestingly, replacing para-hydroxy with para-methoxy
(class F to G) the SPF values increase. Nevertheless, this result is con-
trary to that previously described (class A to B). The best SPF value is
exhibited by compound 4d bearing an -OH in para position of 2-aryl
ring. Protection offered by a sunscreen product against chronic da-
mages (i.e. tumor formation) induced by UVA rays is indicated by UVA-
PF value, which is considered sufficient for protection against UVA by
European regulation if its value results ≥ 1/3 of SPF. Compounds of the
same class presented similar UVA-PF values despite they differ in sub-
stitution at position 6. Compounds 11 h of class F and 11 k of class J,
characterized both by the presence of -OH in meta and para-position of
the phenyl ring, are the best candidate for UVA protection (with UVA-
PF ≈ 7), followed by compounds of class G (3-OH, 4-OMe). Thus, the
effect of the electron donor group (hydroxyl or methoxyl) in the meta
and para position of the 2-aryl ring appears to be important for pro-
tection against UVA.
Critical wavelength (λc) is the parameter that provides information
on the broad spectrum of UV-filter. It is classified in five numerical
categories: 0 (λc < 325 nm), 1 (325 ≤ λc ≤ 335), 2
(335 ≤ λc ≤ 350), 3 (350 ≤ λc <3 7 0) and 4 (λc ≥ 370). FDA
considers that the broad-spectrum sunscreen products should have a
λc ≥ 370 nm [51]. Under that classification, compounds of classes H
and J have fallen into category “4″, as well as compounds 11f (class E),
11t (class G) and 11u (class I). All synthesized compounds showed
λc > PBSA. Thus, very interestingly, compounds of classes H, J and
compounds 11f, 11t and 11u can be considered potential candidate for
broad-spectrum filters.
Finally, we also determined the UVA/UVB absorbance ratio, which
is an important parameter to get information on the absorbance
through the entire UV spectrum. According to the latest EU re-
commendation and PBSA data (the UVA/UVB ratio should be at least 1/
3), all synthesized compounds have good UVA/UVB values, apart from
11o, 4e, 4c and 11n.
2.2.1.2. In vitro sun protection factor of the cosmetic formulation. On the
basis of the results obtained in solution, it was decided to continue the
investigation on compounds of class A and J, representative of
derivatives with the best UVB profile and broad spectrum,
respectively. The 6 molecules synthesized and selected were then
inserted at the concentration of 1% in a conventional cosmetic
formulation O/W in order to deepen their UV-filter activity. The
modified in vitro method of Diffey and Robson [46], based on the
measurement of transmission of ultraviolet radiation on the PMMA
plate, was used. Data of the SPF, UVA-PF, UVA/UVB and λc parameters
are shown in Table 2.
Taking into consideration the spectral data of diluted solutions and
cosmetic formulations, we can affirm that the structure-activity re-
lationship is in principle maintained in both cases. Compound 11 k,
characterized by the presence of three hydroxy groups in position 2,4,5
of the 2-aryl ring, showed the best SPF value (SPF = 3.91). This value is
significant since the formulation contains only 1% of active ingredient.
Compounds 4 k, 11 k, and 11v of class J have confirmed their profile
and are therefore potential compounds for broad-spectrum UV filters. In
vitro data of the formulations indicated that the presence of auxocromes
influences the photoprotective profile..
2.2.1.3. Photostability study. Photostability of selected compounds was
evaluated using one of the criteria developed by Garoli at al. [52],
based on the measurement of SPF before and after exposition. The loss
of sunscreen protection after exposure to sunlight is expressed as the
residual effectiveness after exposure (%). The in vitro % SPFeff. and %
UVA-PFeff. of compounds are calculated according to Eqs. (6) and (7)
respectively and are reported in Table 3. A sunscreen was considered
photostable if its residual percentage is greater than or equal to 80%.
From the results obtained, % SPFeff. and % UVA-PFeff. values of
compounds ranged from 94.06 to 100%. Therefore, these compounds
are considered photostable with a degradation rate less than 6%.
Interestingly, the substitution of the benzothiazole ring in position 6
with -COOH or -SO2NH2 increases the photostability of the compounds.
2.2.2. Antioxidant activity
The synthesized compounds were then tested in vitro to evaluate the
antioxidant activity which, if present, is very important and synergistic
with the SPF described above in reducing UV-induced ROS damages.
The method employed were DPPH and FRAP assays (Table 4).
2.2.2.1. DPPH radical scavenging activities. To better understand the
results of the DPPH test, we first evaluated the percentage of inhibition
of the DPPH radical of synthesized compounds at the same
concentration, namely 1 mg/mL. Compounds of classes F (3,4-
dihydroxyaryl) and H (2,5-dihydroxyaryl) have a percentage of
inhibition close to 100%. However, the substitution of -OH with
-OCH3 to obtain class G (3-hydroxy, 4-methoxy), lead to a decreases
of the percentage of inhibition. Compounds of class A, with -OH in para
position on the 2-aryl ring, did not exhibit any particular activity with
respect to the radical under consideration. In this case, replacing -OH
with -OCH3 to obtain class B compounds lead to a considerably increase
of the percentage of inhibition compounds 4e and 11e In addition,
among compounds of class D, only 11m with -OH in ortho position of 2-
aryl ring and SO2NH2 in 6 position of the benzothiazole ring displayed a
good inhibition. Alike, for compounds of class C (meta-hydroxy), only
compound 11c with COOH in 6-position on benzothiazole ring has
good inhibition. The introduction of methoxy group at position 4 of the
2-aryl ring (compounds of class G) drastically reduced the activity in
comparison to compounds of class F, due to the lack of stabilization.
Based on this first screening, only compounds with good inhibition
(% ≥ 50) were further investigated for the determination of IC50 va-
lues. The results are expressed in µg/mL (Table 4). Structure-activity
relationship analysis indicated that various factors such as the nature of
Table 2
Photoprotection results of 1% benzothiazole selected derivatives in O/W for-




SPF UVA-PF UVA/UVB λc (nm)
PBSA 3.02 ± 0.89 1.04 ± 0.06 0.26 333
4d 3.2 ± 0.21 1.20 ± 0.11 0.63 350
A 11d 1.57 ± 0.09 1.79 ± 0.10 1.12 353
11o 1.99 ± 0.18 3.59 ± 0.24 1.35 351
4k 3.66 ± 0.29 3.24 ± 0.26 0.81 385
J 11 3.91 ± 0.24 3.33 ± 0.11 0.86 388
11v 2.82 ± 0.19 3.26 ± 0.25 1.15 385
Table 3
Evaluation of photostability of 1% benzothiazole selected formulations. Each
value is the mean of three independent measurements (mean ± SEM).
Classes Compound %SPFeff. %UVA-PFeff.
4d 94.06 ± 0.04 98.07 ± 0.23
A 11d 97.45 ± 0.08 99.85 ± 0.35
11o 95.21 ± 0.73 100.0 ± 0.04
4k 94.28 ± 3.07 98.64 ± 2.09
J 11k 97.37 ± 0.22 99.35 ± 0.17
11v 98.44 ± 1.55 99.76 ± 2.08
E.N. Djuidje, et al. Bioorganic Chemistry 101 (2020) 103960
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substituents in position 6 on benzothiazole ring, the number and also
the position of the electron donor group (-OH and -OCH3) on the 2-aryl
ring are very important for the radical scavenging activity. All com-
pounds of class F and H especially those without electron withdrawing
group on the benzothiazole ring (4h and 4g) showed good inhibition,
with IC50 values between 6.42 and 11.29 µg/mL, respectively. This
could be due to the fact that, polyphenols having two -OH groups in the
2,5- and 3,4-positions react twice with DPPH radical to form a very
stable conjugated diketone structure, further stabilized the hydrogen
bonds between two hydroxy for the 3,4-dihydroxy compounds and
between one hydroxy and nitrogen of the benzothiazole ring for the 2,5-
dihydroxy compounds. Nevertheless, introduction of methoxy group at
position 4 of the 2-aryl ring (compounds of class G) drastically reduced
the activity in comparison to compounds of class F (in term of per-
centage of inhibition), due to the lack of stabilization above mentioned.
Surprisingly, compound 11c with meta-hydroxy group displayed good
activity, while compound 3,5-dihydroxysubstituted on 2-aryl ring have
no activity. In addition, compounds of class J, although having three
-OH group, are less active than their parent compounds (compounds of
class H). This could be explained by the fact that the presence of the
third -OH prevents the resonance.
2.2.2.2. Ferric reducing potential. Similar to DPPH results, the molecules
with a better antioxidant profile are those of classes F and H which bear
two hydroxy groups respectively at positions 3, 4 and 2, 5- of the 2-aryl
ring. The compounds of classes A and D, having para and ortho hydroxy
on the 2-aryl ring respectively, have moderate values. Among
compounds of class C, 11c bearing -COOH on the benzothiazole ring
have a good activity (2045.37 ± 18.68 μmolT/g), instead both 4c and
11n have very low values (48.61 ± 0.40 and 17.36 ± 0.81μmolT/g
respectively). The substitution of the hydroxyl group in para (class A)
with a methoxyl (class B) did not lead to significant changes in the
activity, except for the compound 11d, whose correspondent 11e has
more than halved activity. Instead the replacement of the para methoxy
group (class G) with an hydroxyl group (Class F) led to a significant
increase in activity, indicating that para methoxy substitution is not
suitable for this activity.
In summary, considering the above mentioned results, in DPPH and
FRAP assays, molecules with better antioxidant profile are compounds
of classes F and H, which bear two hydroxy groups at positions 3, 4 and
2, 5- of the 2-aryl ring.
2.2.3. Antifungal activity
2.2.3.1. Antidermatophytic activity. All synthesized compounds were
investigated to determine their antifungal activity against five
dermatophytes responsible for the most common dermatomycoses:
Microsporum gypseum, Microsporum canis, Trichophyton mentagrophytes,
Trichophyton tonsurans and Epidermophyton floccosum. Inhibition of
dermatophytes was evaluated by inhibition growth method in
Sabouraud Dextrose Agar (SDA), using DMSO as a solvent. All
compounds were tested at a concentration of 100 μg/ml (Tables S2).
Compound 4h showed the highest antifungal activity. It is active
against all five dermatophytes, in particular against M. gypseum, T.
tonsurans and E. floccosum with a percentage of inhibition close to
100%. Significant activity was observed for compounds 4f and 4g
againstM. gypseum and E. floccosum. Compound 4c and 4j showed good
activity against Microsporum gypseum and Epidermophyton floccosum
respectively. In general it can be stated that compounds substituted in
position 6 of the benzothiazole ring showed a reduced activity, thus
suggesting that electron withdrawing substituent decrease the
antifungal activity.
In addition compound 4h, identified as the most active in the pre-
vious screening, was also evaluated for its potency against M. gypseum,
T. tonsurans and E. floccosum as reported in Table 5.
2.2.3.2. Anti-Candida activity. The antifungal activity of the
synthesized compounds was also determined against Candida albicans
(ATCC 10231). Minimal inhibitory concentration (MIC) of the
Table 4
Antioxidant activity of benzothiazole derivatives. Each value is the mean of three independent measurements (mean ± SEM).
Classes Compound DPPH %Inhibition DPPH IC50 (µg/ml) FRAP µmolT/g
4a 43.6 ± 0.11 974.49 ± 4.78 167.01 ± 3.34
4d 11.60 ± 0.32 – 123.00 ± 5.92
A 11d 30.75 ± 0.89 – 402.17 ± 1.95
11o 31.22 ± 0.45 – 65.60 ± 1.18
4e 45.27 ± 0.61 – 206.88 ± 6.64
B 11e 71.70 ± 0.58 322.70 ± 6.29 173.83 ± 5.05
11p 15.48 ± 0.33 – 90.95 ± 3.64
4c 16.27 ± 0.06 – 48.61 ± 0.40
C 11c 94.64 ± 1.22 28.97 ± 0.56 2045.37 ± 18.68
11n 22.73 ± 0.69 – 17.36 ± 0.81
4b 30.72 ± 0.47 – 264.75 ± 5.84
D 11b 18.00 ± 0.36 – 20.60 ± 0.85
11m 58.22 ± 0.87 – 197.80 ± 5.07
4f 72.83 ± 0.58 822.63 ± 8.16 187.64 ± 5.15
E 11f 22.37 ± 0.52 – 50.32 ± 1.54
11q 23.89 ± 0.48 – 91.31 ± 3.25
4h 84.65 ± 0.93 7.2 ± 0.11 6021.15 ± 25.84
F 11h 94.74 ± 0.66 11.29 ± 0.07 7402.73 ± 22.78
11s 94.36 ± 0.82 7.96 ± 0.55 5273.01 ± 15.01
4i 65.00 ± 0.31 561.62 ± 18.13 3247.66 ± 56.72
G 11i 28.02 ± 0.87 – 712.52 ± 10.75
11t 10.98 ± 0.11 – 65.39 ± 0.35
4g 94.32 ± 1.15 6.42 ± 0.28 6268.43 ± 25.16
H 11g 96.41 ± 0.89 7.61 ± 0.28 7321.64 ± 34.73
11r 96.23 ± 0.77 9.09 ± 0.24 7115.91 ± 14.46
4j 77.5 ± 4.76 159.55 ± 6.20 273.49 ± 15.38
I 11j 57.9 ± 0.82 – 175.98 ± 1.78
11u 19.93 ± 1.54 – 73.33 ± 1.42
4k 23.78 ± 0.82 – 4876.44 ± 34.54
J 11k 72.73 ± 3.67 43.01 ± 2.93 1960.24 ± 18.43
11v 53.20 ± 0.95 186.89 ± 5.46 513.04 ± 2.66
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synthesized agents was determined by broth microdilution method
using RPMI (Roswell Park Memorial Institute) 1640 + MOPS (3-(N-
Morpholino)propanesulfonic acid sodium salt). The concentration of
the tested compounds ranged from 0.25 µg·mL−1 to 128 µg·mL−1. The
growth in the 96-well microdilution plate was observed visually for
turbidity and inhibition was determined by the absence of growth. MIC
was determined by the lowest concentration of the sample that
prevented the development of turbidity. The results, shown in
Table 6, are representative of 24 and 48 h of incubation arranged in
triplicate (only active compounds against Candida albicans were
shown). Fluconazole was used as referenced compound. Derivative
4h, 4f, 4k, showed good activity. In particular, compounds 4f and 4k
characterized respectively by the presence of -OH groups in positions 2,
4 and 2, 4, 5 of the 2-aryl ring and no functional group on the
benzothiazole ring are more effective with a range of MIC of 4–8 µg/mL
at 24 h.
2.2.4. Antiproliferative activity
Antiproliferative activities of target compounds against human T
cell leukemia cell line (CEM), human cervix carcinoma cells (HeLa),
human pancreas carcinoma cells (Mia Paca-2) and human melanoma
cells (SK-Mel 5) were evaluated in vitro and summarized in Table 7. The
results were expressed as IC50 values in µM and normal kidney epi-
thelial cells (HEK 293) were chosen as control of cytoxicity and/or
selectivity.
Among the tested compounds, 4e, 11n and 11o were the most po-
tent against Mia Paca-2 cells with IC50 values of 6.6, 5.5 and 6.5 μM
respectively, but inactive against HeLa and CEM cells (IC50 > 50 µM).
However, 4e also displayed good activity against SK-Mel5 cells while
11n and 11o were moderately active. Compounds 4g and 4h exhibited
good antiproliferative activity against CEM and SK-Mel 5 cells with
IC50 < 10 μM and a moderate activity against HeLa and Mia Paca-2
(IC50 > 20 µM). 4k showed the best activity against SK-Mel 5 and it
also displayed good inhibitory activity against CEM.
Interestingly, substitution of the para hydroxyl group of compound
4d with a methoxy group led to compound 4e endowed with increased
antiproliferative activity against Mia Paca-2 cell (52 to 6.6 μM respec-
tively). Similarly, the introduction of -SO2NH2 at the 6-position on the
benzothiazole ring (11o) increase potency. Curiously, in this case,
substitution by para-methoxy has the same effect on Mia Paca-2 cell as
substitution by -SO2NH2 in position 6 on benzothiazole, therefore ac-
tivity of 4e is similar to 11o. The shift of the hydroxyl group along 2-
aryl group did not have significant effect on the activity, whereas the
introduction of a second or third hydroxyl group (compound 4g, 4h,
and 4k) led to an increase in the antiproliferative activity on the CEM
and SK-Mel 5 cells.
After introduction of the -SO2NH2 group into the benzothiazole
skeleton of 4c to obtain 11n, an increase in activity against Mia Paca-2
cells was observed but activity against CEM, HeLa and SK-Mel 5 cells
decreased. Apart from 4c and 4d, the introduction of -SO2NH2 into the
backbone reduces the activity against Mia Paca-2 cells. All tested
compounds showed low antiproliferative activity towards HeLa cell
line, except compound 4h with an inhibition activity less than 30 µM.
To our surprise, replacement of the -SO2NH2 with -COOH led to almost
total loss of activity.
Based on cytotoxicity screening, all unsubstituted compounds on the
benzothiazole ring were cytotoxic to normal HEK 293 except compound
4e and 4i with para-methoxy group on 2-aryl ring, suggesting the im-
portance of para-methoxy for antiproliferative activity. As well as 4b
and 4k bearing respectively one and three hydroxy group was not cy-
totoxic. However electron-withdrawing group -SO2NH2 on the ben-
zothiazole ring decreases the cytotoxicity of the target compound ex-
cept compound 11o and 11s characterized by the the presence of para-
hydroxy group on 2-aryl ring. Compounds bearing -COOH on the
benzothiazole ring (11a-11k) were inactive against both normal and
cancer cells.
The Selectivity Index (SI) was determined by comparing the IC50
values (μM) obtained on the healthy cells (HEK 293) with that obtained
on cancer cells (CEM, HeLa, Mia-Paca-2 and SK-Mel 5). From the results
presented in Table 7, we observed that compounds 4e, 11n and 11o
were respectively 15, 18 and 5 fold more selective toward Mia-Paca-2
cells, while compounds 4g and 4k were approximately 6 fold more
selective for CEM cells. In addition, compounds 4e, 4i and 4k showed
selectivity for SK-Mel 5 cells. Compounds 4k were 25 fold more selec-
tive for SK-Mel 5 cells that could be due to the presence of three hy-
droxy groups on the 2-aryl ring. SI values indicated as the best com-
pounds the derivative 11n, selective towards the Mia-Paca-2, the
selective derivative 4e for both the Mia-paca-2 and for the SK-Mel5 and
the 4g and 4k selective derivatives for the CEM and the SK-Mel5. The
particularity of these last two compounds is the presence of -OH in
position 2 and 5 on the 2-aryl ring. Therefore, these two positions are
very important for the activity sought.
2.2.5. Benzothiazole derivatives block hERG potassium channels expressed
in HEK293 cells
In order to have an idea of the possible mechanism of compounds
presenting a good antiproliferative profile, we studied the effect of
these derivatives on the modulation of human ether-a-go-go related
gene (hERG) current. hERG is a gene (KCNH2) that encodes for a
protein highly selective for potassium channel (Kv11.1). These protein
channels are widely expressed, mainly in the cardiac tissues, neuronal
tissues, brain, adrenal gland, thymus, retina and in some cancer cells
[53]. Indeed, the ion channels are transmembrane proteins that reg-
ulate the flow of ions through biological membranes. In particular,
potassium channels represent the most diverse group of ion channels
and play an important role in several functions such as muscle excita-
tion, regulation of blood pressure [54], proliferation of several types of
cancer, such as prostate, colon, and glioma [55–57]. It has been shown
that, hERG potassium channels are overexpressed in many types of
human cancers as well as in primary human cancers [58,59]. In addi-
tion, it was shown that over-expression of hERG channels in HEK-293
cells greatly increased the proliferation, tumor cell invasion and me-
tastasis. The blockade or inhibition of hERG in these cells induced both
antiproliferative and antimigratory effect [60,61]. Thus the interest in
the study of hERG channels has increased exponentially, mainly be-
cause of its involvement in many cellular events such as repolarization
and proliferation of cells [62]. Therefore, given their multifunction,
these channels are potential therapeutic targets for cancer treatment by
Table 5
IC50 values of 4h benzothiazole derivate and Fluconazole. Each value is the
mean of three measurements (mean ± SEM).
IC50 μg/ml
M. gypseum T. tonsurans E. floccosum
4h 26.95 ± 1.04 43.31 ± 1.85 11.63 ± 0.24
Fluconazole 18.5 ± 1.23 19.41 ± 0.87 0.08 ± 0.005
Table 6
Anti-Candida albicans activities of benzothiazole derivatives. The average va-
lues were taken as the MICs.
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application of hERG channel blocking.
One of the most accurate methods for determining the potency of a
compound in K+ channel inhibition is patch-clamp electrophysiology.
In this work we focused on the QPatch automated patch clamp system
to evaluate the blockade of hERG potassium channels expressed in
HEK293 cells. Three different concentrations (0.1, 1 and 10 μM) of
benzothiazole derivatives were tested and summarized in Table 8. E-
4031 (methanesulfonanilide class III antiarrhythmic agent) is the re-
ference compound for this assay. The percent inhibition of the peak tail
current was measured, the concentration of drugs needed to yield a
50% blockade of the hERG current (IC50) was obtained by fitting the
data to a Hill equation (Eq. (10)).
At the higher tested concentration (10 μM) 4g reduced hERG cur-
rent amplitude to 60.32 ± 2.43 %with IC50 equal to 4,79 µM, while
4e, 11c and 11d have an inhibition less than 50%. As compared to the




Reagents and solvents were purchased from Sigma-Aldrich and
Carlo Erba Reagenti (Italia) and without further purification. Analytical
TLC was performed on silica gel plates (Macherey-Nagel Poligram SIL
G/UV254 0.20 mm) and visualized by exposure to ultraviolet light
(254 nm) and /or used 1% solution of KMnO4. Column chromatography
was performed using silica gel Macherey-Nagel 60 M 230,400 mesh. 1H
NMR and 13C NMR were registered with Varian spectrometers at
200 MHz and 400 MHz at room temperature. Chemical shifts are
measured with respect to tetramethylsilane and relative to residual
solvent peaks as an internal standard set to D2O and (CD3)2SO. The
following abbreviations are used to indicate signal multiplicity: s
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), brs (broad
singlet) and dd (doublet of doublets). Molecular weights of the com-
pounds were determined by ESI (Micromass ZMD 2000), and the values
are expressed as [MH]+. UV spectrophotometric analyses were carried
out on a UV–VIS spectrophotometer (Shimadzu UV-2600). IR analyses
were performed on FT-IR spectrometer Spectrum 100 (Perkin Elmer
precisely).
3.2. Chemistry
3.2.1. General method for the synthesis of 2-Arylbenzothiazoles
unsubstituted on the benzothiazole ring
To a solution of 2-aminothiophenol (0.4 g, 3.2 mmol) and aldehyde
(3.2 mmol) in ethanol (3.5 mL) at room temperature was added solu-
tion of sodium hydrosulfite (2 eq. in 3 mL H2O). The mixture was he-
ated at reflux for 12 h. After cooling to room temperature, the solution
was concentrated in vacuo. The residue was treated with HCl 2 N
Table 7
Inhibitory effects of benzothiazole derivatives on the proliferation of CEM, HeLa, Mia Paca-2 and SK-Mel 5. Each value is the mean of three independent mea-
surements (mean ± SEM). SI = IC50 of pure compound in a normal cell line/IC50 of the same pure compound in cancer cell line.
IC50 µM SI
Classes Compound CEM HeLa Mia-Paca-2 SK-Mel5 HEK 293 CEM HeLa Mia-Paca-2 SK-Mel5
Reference 4a >100 100 ≥100 82 ± 23 >100 – – – 1.22
4d 52 ± 0.0 46 ± 10 52 ± 10 51 ± 3 50 ± 2 0.96 1.09 0.96 0.98
A 11d 77 ± 32 >100 >100 >100 >100 1.30 – – –
11o 64 ± 24 67 ± 25 6.5 ± 0.5 33 ± 6 32 ± 4 0.50 0.48 4.92 0.97
4e >100 >100 6.6 ± 3.3 14 ± 2 >100 – – 15.15 7.14
B 11e >100 >100 >100 >100 >100 – – – –
11p >100 >100 47 ± 16 >100 >100 – – 2.13 –
4c 38 ± 2 44 ± 8 62 ± 14 17 ± 10 46 ± 2 1.21 1.05 0.74 2.71
C 11c >100 >100 72 ± 39 >100 >100 – – 1.39 –
11n 58 ± 19 77 ± 12 5.5 ± 3.1 43 ± 1 ≥100 1.72 1.30 18.18 2.33
4b 63 ± 16 93 ± 10 >100 34 ± 10 >100 1.59 1.08 – 2.94
D 11b >100 >100 >100 ≥100 >100 – – – –
11m >100 ≥100 >100 ≥100 >100 – – – –
4f 52 ± 0.0 46 ± 10 52 ± 10 51 ± 3 50 ± 2 0.96 1.09 0.96 0.98
E 11f >100 >100 ≥100 >100 >100 – – – –
11q >100 >100 ≥100 >100 73 ± 38 – – – –
4h 8.2 ± 5.7 29 ± 16 40 ± 21 5.4 ± 0.3 15 ± 4 1.83 0.52 0.38 2.78
F 11h >100 >100 >100 >100 >100 – – – –
11s 19 ± 5 45 ± 9 41 ± 22 25 ± 2 14 ± 5 0.74 0.31 0.34 0.56
4i 51 ± 15 ≥100 >100 25 ± 3 ≥100 1.96 – – 4.00
G 11i >100 >100 80 ± 25 95 ± 7 >100 – – 1.25 1.05
11t 59 ± 13 80 ± 29 ≥100 >100 ≥100 1.69 1.25 – –
4g 2.0 ± 1.6 74 ± 29 38 ± 3 5.3 ± 0.5 13 ± 5 6.50 0.18 0.34 2.45
H 11g >100 >100 66 ± 35 >100 >100 – – 1.52 –
11r 22 ± 6 90 ± 14 72 ± 21 >100 62 ± 17 2.82 0.69 0.86 –
4j 32 ± 5 38 ± 6 52 ± 4 28 ± 2 33 ± 9 1.03 0.87 0.63 1.18
I 11j >100 >100 ≥100 >100 >100 – – – –
11u 89 ± 15 >100 ≥100 74 ± 6 ≥100 1.12 – – 1.35
4k 18 ± 2 >100 >100 4.0 ± 0.2 > 100 5.56 – – 25.00
J 11k 91 ± 13 >100 >100 64 ± 26 >100 1.10 – – 1.56
11v >100 >100 >100 >100 >100 – – – –
Table 8
Inhibition of hERG channels by benzothiazole derivatives tested at 10 µM. Each
value is the mean of three independent measurements (mean ± SEM).
Compound hERG activity channels
pIC50 % Inhibition
4e <5 12.09 ± 5.05
4 g 5.32 ± 0.04 60.32 ± 2.43
4 k <5 41.17 ± 2.94
11c <5 20.73 ± 1.79
11d <5 8.07 ± 4.08
E-4031 7.55 ± 0.08 96.32 ± 0.9
E.N. Djuidje, et al. Bioorganic Chemistry 101 (2020) 103960
8
(15 mL) and filtered to obtain the crude solid, which was recrystallized
from appropriate solvent. Compounds 4b, 4e and 4f were synthesized
with and without catalyst following the same procedure described
above.
3.2.1.1. 2-phenylbenzo[d]thiazole (4a). Yield 60%; white solid; m.p.
98–99 °C; UV λmax 298.4 nm. IR (KBr) cm−1: 3446.7, 1589.75, 1474.3,
1316.4, 1217.2, 756.9. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 8.10 (d,
J= 8 Hz, 1H, BTZ), 8.01 (d, J= 8 Hz, 1H, BTZ), 7.74 (m, 2H, Ar), 7.33
(m, 5H, 2H BTZ, 3H Ar). 13C NMR (400 MHz, DMSO‑d6): δ (pmm)
169.45, 154.4, 143.65, 133.32, 131.87, 130.32, 129.00, 126.76,
124.54, 123.67, 120.09. ESI-M [M+H]+: calcd for C13H9NS, 211.28;
found 212.20.
3.2.1.2. 2-(2-hydroxyphenyl)benzo[d]thiazole (4b). Yield 80%; yellow
solid; m.p. 125–126.4 °C; UV λmax 331.4 nm. IR (KBr) cm−1: 3000.5,
1589.1, 1479.8, 1315.2, 1214.4, 724.7. 1H NMR (400 MHz, DMSO‑d6):
δ (ppm) 11.65 (brs, 1H, OH), 8.21–8.18 (2H, m, BTZ), 8.07 (d,
J = 8 Hz, 1H, Ar), 7.58 (t, 1H, BTZ), 7.39 (m, 2H, 1H BTZ, 1H Ar),
7.15 (d, J = 8.0 Hz, 1H, Ar), 7.01 (t, J = 7.2 Hz, 1H, Ar). 13C NMR
(400 MHz, DMSO‑d6): δ (pmm) 165.59,156.65, 151.83, 134.68, 132.95,
128.95, 126.94, 125.56, 122.54, 122.45, 120.25, 118.76, 117.38. ESI-
MS [M+H]+: calcd for C13H9NOS, 227.28; found 228.17.
3.2.1.3. 2-(3-hydroxyphenyl)benzo[d]thiazole (4c). Yield 71%; yellow
solid; m.p. 158–159 °C; UV λmax 299.4 nm. IR (KBr) cm−1: 3251.3,
1598.0, 1453.6, 1317.1, 1231.3, 759.0. 1H NMR (400 MHz, DMSO‑d6):
δ (ppm) 9.93(brs, 1H, OH), 8.19 (d, J = 8.0 Hz, 1H, BTZ), 8.08 (d,
J = 8.0 Hz, 1H, BTZ), 7.60–7.39 (m, 3H BTZ, 2H Ar), 6.99 (dd,
J = 8.4 Hz, J = 1.6HZ, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ
(pmm) 167.79, 158.42, 153.94, 134.80, 134.45, 131.03, 127.09,
125.97, 123.30, 122.79, 118.99, 118.54, 113.83. ESI-MS [M+H]+:
calcd for C13H9NOS, 227.28; found 228.30.
3.2.1.4. 2-(4-hydroxyphenyl)-benzo[d]thiazole (4d). Yield 78%; yellow
solid; m.p. 224–225 °C; UV λmax 323.5 nm. IR (KBr) cm−1: 3200.5,
1603.5, 1424.7, 1283.5, 754.4. 1H NMR (400 MHz, DMSO‑d6): δ (ppm)
10.22 (brs, 1H, OH), 8.08 (d, J = 8.0 Hz, 1H, BTZ), 7.98–7.96 (m, 3H,
BTZ), 7.56–7.38 (m, 2H, Ar), 6.91 (d, J = 8.4 Hz, 2H, Ar). 13C NMR
(400 MHz, DMSO‑d6): δ (pmm) 167.90, 160.95, 154.166, 134.54,
129.48, 126.87, 125.34, 124.47, 122.73, 122.56, 116.54. ESI-MS [M
+H]+: calcd for C13H9NOS, 227.28; found 228.18.
3.2.1.5. 2-(4-methoxyphenyl)-benzo[d]thiazole (4e). Yield 82%; white
solid; m.p. 118–119 °C; UV λmax 321.4 nm. IR (KBr) cm−1: 2996.0,
2835.9, 1589.1, 1433.6, 1224.4, 1170.7, 751.7. 1H NMR (400.0 MHz,
DMSO‑d6): δ (ppm) 8.24 (d, J= 8.0 Hz, 1H, BTZ), 8.18 (d, J= 8.0 Hz,
1H, BTZ), 7.90 (d, J = 8.0 Hz, 2H, Ar), 7.75 (t, J = 6.4 Hz, 1H, BTZ),
7.70 (t, J= 6.4 Hz,1H, BTZ), 7.17 (d, J = 8.4 Hz, 2H, Ar), 3.92 (s, 3H,
OCH3). 13C NMR (400 MHz, DMSO‑d6): δ (pmm) 167.50, 162.23,
154.09, 134.65, 129.33, 126.99, 125.95, 125.57, 122.90, 122.67,
115.21, 55.95. ESI-MS [M+H]+: calcd for C14H11NOS, 241.06: found
242.27.
3.2.1.6. 2-(2,4-dihydroxyphenyl)-benzo[d]thiazole (4f). Yield 68%;
yellow solid; m.p. 212–213 °C; UV λmax 337.0 nm. IR (KBr) cm−1:
3446.7, 1599.8, 1474.3, 1217.2, 756.9. 1H NMR (400 MHz, DMSO‑d6):
δ (ppm) 9.22 (brs, 2H, OH), 8.18 (d, J = 8.0HZ, 1H, BTZ), 8.01 (d,
J = 8.0HZ, 1H, BTZ), 7.56–7.46 (m, 3H, 2H BTZ, 1H Ar), 6.42 (d,
J = 8 Hz, 1H, Ar), 6.33(s, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ
(pmm) 162.01, 158.65, 151.91, 133.73, 130.48, 126.78, 124.95,
122.31, 121.86, 110.65, 108.89, 103.072. ESI-MS [M+H]+: calcd for
C13H9NO2S, 243.04; found 244.11.
3.2.1.7. 2-(2,5-dihydroxyphenyl)-benzo[d]thiazole (4g). Yield 58%;
yellow solid; m.p. 220–221 °C; UV λmax 295.2, 362.8 nm. IR (KBr)
cm−1: 3332.8, 1579.8, 1496.0, 1197.2, 756.5. 1H NMR (400.0 MHz,
DMSO‑d6): δ(ppm) 10.82 (brs, 1H, OH), 9.18 (brs, 1H, OH), 8.17 (d,
J = 8.0 Hz, 1H, BTZ), 8.01 (d, J= 8.0 Hz, 1H, BTZ), 7.59–7.38 (m, 2H
BTZ, 1H Ar), 6.98–6.82 (m, 2H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ
(pmm) 165.47, 151.93, 150.53, 149.68, 134.83, 126.85, 125.43,
122.51, 122.43, 120.73, 118.82, 118.31, 113.51. ESI-MS [M+H]+:
calcd for C13H9NO2S, 243.04; found 244.14.
3.2.1.8. 2-(3,4-dihydroxyphenyl)-benzo[d]thiazole (4h). Yield 70%;
yellow solid; m.p. 216–217 °C; UV λmax 329.2 nm. IR (KBr) cm−1:
3488.6, 2916.8, 1599.1, 1474.3, 1260.5, 754.1. 1H NMR (400 MHz,
DMSO‑d6): δ (ppm) 9.51 (brs, 2H, OH), 8.12 (d, J = 8.0 Hz, 1H, BTZ),
7.98 (d, J = 8.0 Hz, 1H, BTZ), 7.51 (m, 2H, BTZ), 7.38 (m, 2H, Ar),
6.88 (d, J = 8.4 Hz, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ (pmm)
168.10, 154.06, 149.40, 146.22, 134.47, 126.88, 125.34, 124.73,
122.52, 119.92, 118.56, 116.54, 114.36. ESI-MS [M+H]+: calcd for
C13H9NO2S, 243.04; found 244.29.
3.2.1.9. 2-(3-hydroxy-4-methoxyphenyl)-benzo[d]thiazole (4i). Yield
65%; white solid; m.p. 184–185 °C; UV λmax 326.4 nm. IR (KBr)
cm−1: 3252.3, 1597.4, 1474.3, 1122.7, 763.9. 1H NMR (400 MHz,
DMSO‑d6): δ (ppm) 9.49 (brs, 1H, OH), 8.08 (d, J = 8.0 Hz, 1H, BTZ),
7.98 (d, J= 8.0 Hz, 1H, BTZ), 7.56–7.46 (m, 3H, 1H BTZ, 2H Ar), 7.40
(t, J = 7.2 Hz, 1H, BTZ), 7.01(d, J = 8.4 Hz, 1H, Ar), 3.85 (s, 3H, Ar).
13C NMR (400 MHz, DMSO‑d6): δ (pmm) 167.77, 154.04, 151.07,
147.37, 134.62, 126.93, 126.07, 125.50, 122.85, 122.57, 119.62,
113.98, 112.76, 56.12. ESI-MS [M+H]+: calcd for C14H11NO2S,
257.31; found 258.29.
3.2.1.10. 2-(3,5-dihydroxyphenyl)-benzo[d]thiazole (4j). Yield 58%;
yellow solid; m.p. 225–226 °C; UV λmax 302.0 nm. IR (KBr) cm−1:
3068.7, 1606.9, 1438.3, 1147.9, 755.6. 1H NMR (400 MHz, DMSO‑d6):
δ (ppm) 10.01–10.22(brs, 2H, OH), 8.05 (d, J= 8.0 Hz, 1H, BTZ), 7.96
(d, J= 8.0 Hz, 1H, BTZ), 7.38–7.56 (m, 2H, BTZ), 6.96 (d, J = 2.0 Hz,
2H, Ar), 6.39 (s, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ (pmm)
167.43, 158.96, 153.35, 134.28, 134.13, 126.45, 125.33, 122.70,
122.16, 105.34, 105.05. ESI-MS [M+H]+: calcd for C13H9NO2S,
243.04; found 244.19.
3.2.1.11. 2-(2,4,5-trihydroxyphenyl)-benzo[d]thiazole (4k). Yield 51%;
grey solid; m.p. 225–226 °C; UV λmax 295.6, 365.4 nm. IR (KBr) cm−1:
3068.8, 1603.2, 1437.8, 1150.3, 756.1. 1H NMR (400 MHz, DMSO‑d6):
δ (ppm) 9.48 (brs, 3H, OH), 8.16 (d, J = 8.0 Hz, 1H, BTZ), 8.01 (d,
J = 8.0 Hz, 1H, BTZ), 7.64 (m, 2H, BTZ), 6.65 (s, 1H, Ar), 6.32 (s, 1H,
Ar). 13C NMR (400 MHz, DMSO‑d6): δ (pmm) 166.73, 151.51, 150.86,
150.39, 138.90, 133.29, 126.16, 124.21, 121.70, 121.19, 113.37,
108.68, 103.48. ESI-MS [M+H]+: calcd for C13H9NO3S, 259.03;
found 260.18.
Following the general procedure compounds 6 and 7 were prepared
and their analytical and spectra dare are in agreement with those re-
ported in literature [44].
3.2.2. 2-aminobenzo[d]thiazole-6-sulfonamide (9)
4-amino-benzenesulfonamide (5.00 g, 0.029 mol) and potassium
thiocyanate (5.64 g, 0.058 mol) were dissolved in glacial acetic acid
(45 mL). The mixture was stirred at room temperature for 20 min and
then a bromine solution (1.49 mL 0.029 mol) in acetic acid glacial
(5 mL) was added with a dropping funnel. After the addition, the
mixture was kept under stirring at room temperature for 24 h. The
precipitated solids were collected by filtration and obtained solid was
dissolved in H2O·NH3 30% (about 2 mL) was added to the solution to
bring the solution up to a pH8-9 and placed in the refrigerator over-
night. The precipitated solids were collected by filtration and the pro-
duct was washed with H2O. The white product was dried and purified
by recrystallization in EtOH to obtain 3.01 g of 9 as a white solid, with a
yield of 45%. m.p. > 250 °C. UV λmax 305.90 nm. 1H NMR (400 MHz,
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DMSO‑d6): δ (ppm) δ 8.23 (1H, d), 7.96–7.84 (2H, dd), 7.02–6.83 (2H,
d). 13C NMR (400 MHz, DMSO‑d6): δ (pmm) 166.53, 156.34, 136.10,
125.36, 123.63, 121.59, 115.33. ESI-MS [M+H]+: calcd for
C7H7N3O2S2, 229.28; found 230.09.
3.2.3. bis(2-amino-4-benzenesulfonamide) disulfide (10)
To the 2-amino-benzotiazole-6-sulfonamide (3 g, 0.013 mol), a KOH
solution (3.95 g of KOH in 5.8 mL of H2O) was added, which was
subsequently refluxed for 8 h. After cooling, 35% HCl (about 2 mL) was
added at −5° C until PH ≈ 8. The mixture was placed in refrigerator,
left overnight and then filtered. The solid product was washed with H2O
and subsequently dried and recrystallized in EtOH to obtain 2.20 g
(0.0054 mol) of 10 as a yellow solid, with a yield of 32%. m.p.
243–249 °C. UV λmax 355.1 nm. 1H NMR (400 MHz, DMSO‑d6): δ (ppm
7.59 (1H, d, H6), 7.39(1H, m), 7.28 (2H, brs), 6.75(1H, m), 6.26 (2H,
br). 13C NMR (400 MHz, DMSO‑d6): δ (pmm) 153.03, 133.99, 130.72,
129.60, 115.52, 114.59. ESI-MS [M+H]+: calcd for C12H14N4O4S4,
405.99; found 406.45.
3.2.4. General method for the synthesis of 2-Arylbenzothiazoles substituted
on the benzothiazole ring
To a solution of 4-amino-3-mercaptobenzoic acid (0.49 g, 2.9 mmol)
or bis(2-amino-4-benzenesulfonamide) disulfide (2.35 g, 5.8 mmol) and
corresponding benzaldehydes in ethanol (10 mL) was added a solution
of sodium hydrosulfite (1 eq. in 5 mL H2O) at room temperature. The
mixture was heated at reflux for 36 h. After cooling, the solution was
concentrated in vacuum. The residue was treated with HCl 2 N (15 mL)
and filtered to obtain the crude solid, which was recrystallized in
MeOH/H2O.
3.2.4.1. 2-(2-hydroxyphenyl)benzo[d]thiazole-6-carboxylic acid (11b). Yield
71%; yellow solid; m.p. > 250 °C; UV λmax 338.5 nm. IR (KBr) cm−1:
3111.6, 1677.8, 1590.6, 1481.8, 1217.7, 1167.1, 739.9. 1H NMR (400 MHz,
DMSO‑d6) δ (pmm) 11.40 (br, 1H, COOH), 9.82 (brs, 1H, OH), 8.61 (s, 1H,
BTZ), 8.12 (d, J = 8.4 Hz, 1H, BTZ), 7.74.7.68 (m, 2H, 1H BTZ, 1H Ar),
7.47 (t, J = 6.8 Hz, 1H, Ar), 7.21–7.16 (m, 2H, Ar). 13C NMR (400 MHz,
DMSO‑d6): δ(ppm) 173.46, 171.10, 153.55, 143.3, 132.48, 131.85, 129.48,
127.48, 127.33, 124.28, 122.50, 119.53, 118.78, 115.88. ESI-MS [M+H]+:
calcd for C14H9NO3S, 271.03; found 272.24.
3.2.4.2. 2-(3-hydroxyphenyl)benzo[d]thiazole-6-carboxylic acid (11c). Yield
55%; yellow solid; m.p. > 250 °C; UV λmax 301.1 nm. IR (KBr) cm−1:
3110.6, 1676.6, 1582.6, 1481.6, 1217.6, 1142.4, 769.5. 1H NMR (400 MHz,
DMSO‑d6): δ (ppm) 11.62 (brs, 1H, -COOH), 9.34 (brs, 1H, OH), 8.49 (s, 1H,
BTZ), 8.02 (d, J=8.4 Hz, 1H, BTZ), 7.71 (d, J=8.4 Hz, 1H, BTZ), 7.56 (d,
J= 8.4 Hz, 1H, Ar), 7.28 (t, 1H, Ar), 7.11 (s, 1H, Ar), 6.95 (d, J= 8.4 Hz,
1H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ(ppm) 167.38, 167.20, 156.84,
153.86, 146.96, 134.64, 132.67, 128.38, 127.21, 123.68, 121.49, 119.30,
118.58, 116.96. ESI-MS [M+H]+: calcd for C14H9NO3S, 271.03; found
272.31.
3.2.4.3. 2-(4-hydroxyphenyl)benzo[d]thiazole-6-carboxylic acid (11d). Yield
67%; yellow solid; m.p. > 250 °C; UV λmax 334.3 nm. IR (KBr) cm−1:
3259.1, 1680.9, 1587.4, 1418.4, 1240.2, 1167.0, 770.5. 1H NMR (400 MHz,
DMSO‑d6): δ (ppm) 10.89 (brs, 1H, OH), 9.78 (brs, 1H, OH), 8.68 (s, 1H,
BTZ), 8.05 (d, J=8.4 Hz, 1H, BTZ), 7.72 (d, J=8.4 Hz, 1H, BTZ), 7.59 (d,
J = 8.4 Hz, 2H Ar), 6.99 (d, J = 8.4 Hz, 2H, Ar). 13C NMR (400 MHz,
DMSO‑d6): δ(ppm) 177.53, 167.38, 161.56, 157.00, 134.70, 132.53,
131.18, 129.82, 127.88, 127.43, 124.59, 124.12, 122.41, 116.65. ESI-MS
[M+H]+: calcd for C14H9NO3S, 271.03; found 272.20.
3.2.4.4. 2-(4-methoxyphenyl)benzo[d]thiazole-6-carboxylic acid (11e). Yield
82%; yellow solid; m.p. > 250 °C; UV λmax 331.9 nm. IR (KBr) cm−1:
2980.8, 1683.0, 1592.8, 1480.2, 1263.2, 1085.4, 712.0. 1H NMR (400 MHz,
DMSO‑d6): δ (ppm) 9.87 (brs, 1H, OH), 8.75 (s, 1H, BTZ), 8.17 (d,
J = 8.4 Hz, 1H, BTZ), 7.87 (d, J = 8.4 Hz, 1H, BTZ), 7.14 (m, 4H, Ar)
3.8 (s, 3H, OCH3). 13C NMR (400 MHz, DMSO‑d6): δ(ppm) 179.26, 170.57,
166.81, 162.12, 156.44, 134.28, 129.11, 127.38, 125.11, 124.14, 122.06,
114.77, 65.42. ESI-MS [M+H]+: calcd for C15H11NO3S, 285.32; found
286.27.
3.2.4.5. 2-(2,4-dihydroxyphenyl)benzo[d]thiazole-6-carboxylic acid
(11f). Yield 53%; yellow solid; m.p. > 250 °C; UV λmax 345.5 nm.
IR (KBr) cm−1: 3351.2, 1674.1, 1577.9, 1481.5, 1216.8, 1090.2, 779.9.
1H NMR (400 MHz, DMSO‑d6): δ (ppm) 10.22 (brs, 2H, OH), 8.79 (s,
1H, BTZ), 7.99 (dd, J = 8 hz, J=1.6 Hz, 2H, BTZ), 7.79 (d, J=8.4 Hz,
1H, Ar), 6.58 (s, 1H, Ar), 6.39 (d, J = 8.4 Hz, 1H, Ar). 13C NMR
(400 MHz, DMSO‑d6): δ (ppm) 169.42, 166.99, 162.11, 152.93, 135.48,
133.66, 129.89, 128.16, 122.84, 120.21, 111.51, 108.04, 104.64,
103.29. ESI-MS [M+H]+: calcd for C14H9NO4S, 287.29; found 288.30.
3.2.4.6. 2-(2,5-dihydroxyphenyl)benzo[d]thiazole-6-carboxylic acid
(11g). Yield 75%; yellow solid; m.p. > 250 °C; UV λmax 305.9,
371.6 nm. IR (KBr) cm−1: 3440.7, 2533.3, 1676.8, 1596.9, 1493.6,
1288.5, 1180.4, 780.5. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 13.07
(brs, 1H, OH), 10.82 (s, 1H, OH), 9.19 (s, 1H, OH), 8.71 (d, J= 1.2 Hz,
1H, BTZ), 8.07–8.02 (m, 2H, BTZ), 7.67(d, J = 2.8 Hz, 1H, Ar),
6.85–6.92 (m, 2H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ (ppm),
167.50, 154.77, 149.91, 127.64, 124.52, 122.25, 121.25, 119.14,
118.28, 113.48, 110.00. ESI-MS [M+H]+: calcd for C14H9NO4S,
287.29; found 288.23.
3.2.4.7. 2-(3,4-dihydroxyphenyl)benzo[d]thiazole-6-carboxylic acid
(11h). Yield 69%; yellow solid; m.p. > 250 °C; UV λmax 346.2 nm.
IR (KBr) cm−1: 3487.4, 1681.8, 1594.1, 1417.7, 1274.7, 1180.8, 770.3.
1H NMR (400 MHz, DMSO‑d6): δ (ppm) 12.90 (brs, 1H, OH), 9.78 (s,
1H, OH), 9.45 (s, 1H, OH), 8.64 (s, 1H, BTZ), 8.02 (m, 2H, 1H BTZ, 1H
Ar), 7.55 (d, J = 1.2 Hz, 1H, BTZ), 7.43 (d, J = 8.2 Hz, 1H, Ar), 6.92
(d, J = 8.2 Hz, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ (ppm)
171.12, 166.85, 156.46, 149.48, 145.77, 134.12, 127.29, 126.81,
123.99, 123.89, 121.83, 119.77, 116.09, 114.00. ESI-MS [M+H]+:
calcd for C14H9NO4S, 287.23; found 288.23.
3.2.4.8. 2-(3-hydroxy-4-methoxyphenyl)benzo[d]thiazole-6-carboxylic
acid (11i). Yield 69%; yellow solid; m.p. > 250 °C; UV λmax
341.1 nm. IR (KBr) cm−1: 3547.6, 2956.4, 1702.9, 1587.4, 1477.6,
1217.2, 1142.4, 769.5. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 9.68
(brs, 1H, OH), 8.72 (s, 1H, BTZ), 8.05 (d, J = 8 Hz, 2H, BTZ), 7.58 (d,
J = 8 Hz, 1H, Ar), 7.50 (s, 1H, Ar) 7.11 (d, J = 8 Hz, 1H, Ar), 3.84 (s,
3H, OCH3). 13C NMR (400 MHz, DMSO‑d6): δ (ppm) 171.11, 167.46,
156.74, 151.51, 147.47, 134.72, 127.93, 125.79, 124.52, 122.47,
119.93, 114.09, 112.82, 56.46. ESI-MS [M+H]+: calcd for
C15H11NO4S, 301.04; found 302.19.
3.2.4.9. 2-(3,5-dihydroxyphenyl)benzo[d]thiazole-6-carboxylic acid
(11j). Yield 59%; yellow solid; m.p. > 250 °C; UV λmax 313.2 nm.
IR (KBr) cm−1: 3481.4, 1681.0, 1589. 8, 1423.2, 1270.1, 1182.9,
772.8. 1H NMR (400 MHz, DMSO‑d6) δ: (ppm) 10.78 (brs, 2H, OH),
8.84 (s, 1H, BTZ), 8.18 (d, J = 8 Hz, 1H, BTZ), 7.85 (d, J = 8 Hz, 1H,
BTZ), 6.95 (s, 2H, Ar), 6.25 (s, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6):
δ (ppm) 170.10, 166.46, 158.73, 157.49, 136.60, 133.72, 133.63,
127.03, 123.92, 122.13, 105.51, 104.57. ESI-MS [M+H]+: calcd for
C14H9NO4S, 287.23; found 288.12.
3.2.4.10. 2-(2,4,5-trihydroxyphenyl)benzo[d]thiazole-6-carboxylic acid
(11k). Yield 63%; grey solid; m.p. > 250 °C; UV λmax 378.0 nm.
IR (KBr) cm−1: 3498.0, 1689. 7, 1611.5, 1455.0, 1277. 5, 1186.0,
775.3. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 10.24 (brs, 3H, OH),
8.90 (s, 1H, BTZ), 8.23(d, J = 8 Hz, 1H, BTZ), 8.07 (d, J = 8 Hz, 1H,
BTZ), 6.96 (s, 1H, Ar), 6.19 (s, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6):
δ (ppm) 170.45, 166.11, 157.14, 155.56, 149.12, 138.45, 135.38,
126.70, 125.76, 122.09, 121.05, 113.41, 108.50, 107.17. ESI-MS [M
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+H]+: calcd for C14H9NO5S, 303.02; found 304.23.
3.2.4.11. 2-(2-hydroxyphenyl)benzo[d]thiazole-6-sulfonamide
(11m). Yield 78%; yellow solid; m.p. > 250 °C; UV λmax 335.6 nm.
IR (KBr) cm−1: 3316.0, 3242.7, 1584.2, 1483.7, 1312.7, 1151.5, 746.0.
1H NMR (400 MHz, DMSO‑d6): δ 9.82 (brs, 1H, OH), 8.48 (s, 1H, BTZ),
7.96 (d, J = 8.2 Hz, 1H, BTZ), 7.82 (d, J = 8.2 Hz, 1H, BTZ), 7.64 (d,
J= 8.2 Hz, 1H, Ar), 7.36 (t, 1H, Ar), 7.28 (brs, 2H, NH2), 7.08–6.95(m,
2H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ (ppm) 177.67, 156.83,
154.66, 140.63, 135.33, 133.45, 129.02, 124.35, 122.86, 120.47,
120.04, 119.09, 117.34. ESI-MS [M+H]+: calcd for C13H10N2O3S2,
306.01; found 307.19.
3.2.4.12. 2-(3-hydroxyphenyl)benzo[d]thiazole-6-sulfonamide
(11n). Yield 78%; yellow solid; m.p. > 250 °C; UV λmax 299.5 nm. IR
(KBr) cm−1: 3312.9, 3206.3, 1584.6, 1461.6, 1300.8, 1290.4, 1152.4,
780.0. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 9.28 (brs, 1H, OH), 8.51
(s, 1H, BTZ), 8.02 (d, J = 8.2 Hz, 1H, BTZ), 7.88 (d, J = 8.2 Hz, 1H,
BTZ), 7.54 (d, J= 8.2 Hz, 1H, Ar), 7.38-0.26 (m, 2H, Ar), 7.18 (brs, 2H,
NH2), 6.83 (d, J = 8.2 Hz, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ
(ppm) 170.95, 157.96, 155.05, 140.75, 134.35, 133.47, 130.59,
124.08, 123.05, 120.55, 119.05, 118.23, 113.45. ESI-MS [M+H]+:
calcd for C13H10N2O3S2, 306.01; found 307.22.
3.2.4.13. 2-(4-hydroxyphenyl)benzo[d]thiazole-6-sulfonamide
(11o). Yield 84%; yellow solid; m.p. > 250 °C; UV λmax 331.2 nm. IR
(KBr) cm−1: 3337.2, 3230.2, 1605.7, 1478.3, 1303.0, 1273.0, 1147.8,
832.8. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 10.39 (brs, 1H, OH),
8.58 (s, 1H, BTZ), 8.15 (d, J = 8.2 Hz, 1H, BTZ), 7.94 (d, J = 8.2 Hz,
1H, BTZ), 7.84 (dd, J = 8.2 Hz, J = 1.6 Hz, 2H, Ar), 7.44 (brs, 2H,
NH2), 6.96 (d, J = 8.2 Hz, 2H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ
(ppm) 169.19, 157.72, 152.48, 136.42, 133.16, 129.03, 127.29,
125.95, 123.95, 122.28, 116.56. ESI-MS [M+H]+: calcd for
C13H10N2O3S2, 306.01; found 307.12.
3.2.4.14. 2-(4-methoxyphenyl)benzo[d]thiazole-6-sulfonamide
(11p). Yield 80%; yellow solid; m.p. > 250 °C; UV λmax 328.3 nm. IR
(KBr) cm−1: 3329.4, 3258.2, 1605.4, 1480.2, 1304.0, 1261.2, 1165.2,
829. 9. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 8.59 (s, 1H, BTZ), 8.17
(d, J = 8.2 Hz, 1H, BTZ), 8.09 (dd, J = 8.2 Hz, J = 1.6 Hz, 2H, Ar),
7.97 (d, J= 8.2 Hz, 1H, BTZ), 7.43 (brs, 2H, NH2), 7.18 (d, J= 8.2 Hz,
2H, Ar), 3.83 (s, 3H, -OCH3). 13C NMR (400 MHz, DMSO‑d6): δ (ppm)
171.19, 162.72, 155.81, 140.90, 134.75, 129.70, 125.50, 124.60,
123.14, 120.96, 115.34, 56.02. ESI-MS [M+H]+: calcd for
C14H12N2O3S2, 320.03; found 321.23.
3.2.4.15. 2-(2,4-dihydroxyphenyl)benzo[d]thiazole-6-sulfonamide
(11q). Yield 74%; yellow solid; m.p. > 250 °C; UV λmax 344.5 nm. IR
(KBr) cm−1: 3338.4, 3230.1, 1592.6, 1474.6, 1340.1, 1296.7, 1150.5,
807.5. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 9.84 (brs, 1H, OH), 9.76
(brs, 1H, OH), 8.50 (s, 1H, BTZ), 8.02 (d, J= 8.2 Hz, 1H, BTZ), 7.88 (d,
J= 8.2 Hz, 1H, BTZ), 7.52 (d, J= 8.2 Hz, 1H, Ar), 7.21 (brs, 2H, NH2),
6.48 (m, 1H, Ar), 6.31 (s, 1H, Ar) . 13C NMR (400 MHz, DMSO‑d6): δ
(ppm) 168.84, 162.47, 153.86, 139.97, 133.98, 130.61, 129.60,
124.24, 122.02, 120.46, 114.59, 109.05, 102.97. ESI-MS [M+H]+:
calcd for C13H10N2O4S2, 322.01; found 323.14.
3.2.4.16. 2-(2,5-dihydroxyphenyl)benzo[d]thiazole-6-sulfonamide
(11r). Yield 55%; yellow solid; m.p. > 250 °C; UV λmax 301.0,
369.0 nm. IR (KBr) cm−1: 3347.9, 3263.1, 1601.6, 1496.5, 1342.4,
1215. 5, 1155.5, 765.5. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 10.82
(brs, 1H, OH), 9.2 (brs, 1H, OH), 8.60 (s, 1H, BTZ), 8.19 (d, J= 8.2 Hz,
1H, BTZ) , 7.98 (dd, J = 8.2 Hz, J = 1.6 Hz, 1H, BTZ), 7.64 (d,
J = 1.6 Hz, 1H, Ar), 7.42 (brs, 2H, NH2), 6.98–6.83 (m, 2H, Ar). 13C
NMR (400 MHz, DMSO‑d6): δ (ppm) 167.95, 153.67, 150.57, 149.88,
140.51, 135.44, 124.29, 122.78, 121.32, 120.68, 119.14, 118.27,
113.46. ESI-MS [M+H]+: calcd for C13H10N2O4S2, 322.01; found
322.19.
3.2.4.17. 2-(3,4-dihydroxyphenyl)benzo[d]thiazole-6-sulfonamide
(11s). Yield 69%; yellow solid; m.p. > 250 °C; UV λmax 344.1 nm. IR
(KBr) cm−1: 3499.0, 3307.1, 1603.0, 1490.8, 1335.7, 1279.3, 1145.2,
825.2. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 9.37 (brs, 2H, OH), 8.47
(s, 1H, BTZ), 8.12 (d, J = 8.2 Hz, 1H, BTZ), 7.94 (d, J = 8.2 Hz, 1H,
BTZ), 7.41 (brs, 2H, NH2), 7.28 (d, J= 8.2 Hz, 1H, Ar), 7.03 (s, 1H, Ar),
6.81 (d, J = 8.2 Hz, 1H, Ar). 13C NMR (400 MHz, DMSO‑d6): δ (ppm)
170.12, 155.36, 149.55, 145.80, 140.09, 134.04, 123.92, 123.74,
122.30, 120.25, 119.77, 116.12, 114.04. ESI-MS [M+H]+: calcd for
C13H10N2O4S2, 322.01; found 322.16.
3.2.4.18. 2-(3-hydroxy-4-methoxyphenyl)benzo[d]thiazole-6-sulfonamide
(11t). Yield 78%; yellow solid; m.p. > 250 °C; UV λmax 354.8 nm. IR
(KBr) cm−1: 3329.4, 2957.7, 1605.4, 1486.5, 1313.4, 1270.8, 1169. 9,
826.4. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 9.41 (brs, 1H, OH), 8.48
(s, 1H, BTZ), 8.06 (d, J = 8.1 Hz, 1H, BTZ), 7.92 (d, J = 8.1 Hz, 1H,
BTZ), 7.47 (d, J= 8.1 Hz, 1H, Ar), 7.33 (brs, 2H, NH2), 7.16 (s, 1H, Ar),
6.94 (d, J = 8.1 Hz, 1H, Ar), 3.88 (s, 3H, -OCH3). 13C NMR (400 MHz,
DMSO‑d6): δ (ppm) 168.05, 155.54, 148.98, 145.92, 142.11, 134.51,
122.43, 122.01, 121.79, 120.00, 118.70, 116.86, 114.04, 56.98. ESI-MS
[M+H]+: calcd for C14H12N2O4S2, 336.02; found 337.38.
3.2.4.19. 2-(3,5-dihydroxyphenyl)benzo[d]thiazole-6-sulfonamide
(11u). Yield 63%; yellow solid; m.p. > 250 °C; UV λmax 354.1 nm. IR
(KBr) cm−1: 3499. 7, 3312.1, 1623.3, 1492.2, 1338.2, 1278. 9, 1144.6,
826.1. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 9.48 (brs, 2H, OH), 8.39
(s, 1H, BTZ), 8.01 (d, J = 8.1 Hz, 1H, BTZ), 7.86 (d, J = 8.1 Hz, 1H,
BTZ), 7.40 (brs, 2H, NH2), 6.91 (s, 2H, Ar), 6.35 (s, 1H, Ar). 13C NMR
(400 MHz, DMSO‑d6): δ (ppm) 166.43, 158.23, 157.17, 137.56, 132.80,
132.02, 127.43, 123.55, 122.37, 105.98, 104.24. ESI-MS [M+H]+:
calcd for C13H10N2O4S2, 322.01; found 323.04.
3.2.4.20. 2-(2,4,5-trihydroxyphenyl)benzo[d]thiazole-6-sulfonamide
(11v). Yield 51%; grey solid; m.p. > 250 °C; UV λmax 353.9 nm. IR
(KBr) cm−1: 3350.3, 3264. 8, 1609.5, 1495. 8, 1341.9, 1216.3, 1157.4,
766.8. 1H NMR (400 MHz, DMSO‑d6): δ (ppm) 9.57 (brs, 3H, OH), 8.39
(s, 1H, BTZ), 8.08 (d, J = 8.2 Hz, 1H, BTZ), 7.91 (d, J = 8.2 Hz, 1H,
BTZ), 7.32 (brs, 2H, NH2), 6.88(s, 1H, Ar), 6.41 (s, 1H, Ar). 13C NMR
(400 MHz, DMSO‑d6): δ (ppm) 166.61, 157.90, 150.80, 149.87, 138.15,
133.86, 126.90, 124.45, 121.84, 121.60, 113.90, 111.24, 105.56. ESI-
MS [M+H]+: calcd for C13H10N2O5S2, 338.00; found 339.18.
3.3. Biological studies
3.3.1. Antioxidant activity assays
Free radical Scavenging Activity on DPPH. The following assay is
modified procedure described by Wang at al. [63] The methanolic so-
lution of DPPH (1.5 mL) was added to 0.750 mL of tested sample so-
lutions (solubilized in DMSO and diluted in MeOH) at different con-
centrations (1, 0.5, 0.25, 0.125 and 0.0625 mg/mL). The samples were
kept in the dark at room temperature. After 30 min, the absorbance
values were measured using UV–VIS spectrophotometer at 517 nm
using UV–VIS spectrophotometer and were converted into the percen-
tage antioxidant activity (%) using the Eq. (1).
= ×DPPH\;radical scavenging\;capacity\;(%) [1 A /A ] 100%1 0 (1)
where A0 was the absorbance of the control (without sample) and A1
was the absorbance in the presence of the sample. Linear regression a
plot is carried out for calculating the effective concentration of the
sample required to scavenge 50% of DPPH free radicals.
Ferric Reducing Antioxidant Power (FRAP) assay. Ferric reducing
antioxidant power (FRAP) assay is a widely used method that uses
antioxidants as reductants in a redox-linked colorimetric reaction and it
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is based on the reduction of ferric ions (Fe3+) to ferrous ions (Fe2+) in
the presence of TPTZ (2,4,6- tripyridyl-striazine). This reaction is
monitored by measuring the change in absorbance at 593 nm. The
analysis reagent was prepared according to Benzie [64] procedure by
mixing the following solutions in the reported ratio 10/1/1 (v:v:v): i)
0.1 M acetate buffer pH 3.6, ii) TPTZ 10 mmol/L in 40 mmol/ HCl, iii)
ferric chloride 20 mmol/L. To 1.9 mL of reagent were added 0.1 mL of
sample proper diluted or solvent when blank was performed. FRAP
values are obtained by comparing the absorbance change at 593 nm in
sample solution with the absorbance of the blank reaction, using a
UV–VIS spectrophotometer.
3.3.2. In vitro Photoprotection assay
3.3.2.1. Evaluation of filtering parameters of compounds in solution. Sun
protection factor evaluation was performed by means of a UV–VIS
spectrophotometer SHIMADZU UV-2600 240 V. Test compounds were
dissolved in dimethylsulfoxide at the concentration of 0.0015
(± 0.000005) % and the absorbance was measured between 290 and
400 nm using a 1 cm quartz cell at intervals of one 1 nm using a UV–Vis
Spectrophotometer. The absorbance at wavelength λ is related to the
transmittance (T(λ)) by the Eq. (2)
=A( ) Log[T( )] (2)
where T(λ) is the fraction of incident irradiance transmitted by the
sample.
3.3.2.2. In vitro evaluation of filtering parameters of formulation. The
selected synthesized molecules were included at the concentration of
1% in a topical formulation O/W in order to evaluate their UV -filter
activity
INCI: aqua, glycerin, Euxyl PE 9010, Xanthan gum, ceteareth-12,
ceteareth-20, Sterearic acid, Butylhydroxytoluene, Myritol, PEG-7 gly-
cerylcocoate and sodium solution 10%.
WW5 PMMA plates have been purchased from Schonberg GmbH
(Munich, Germany). 32.5 mg of each compound formulation O/W were
spread onto 5 × 5 cm2 PMMA plates in small droplets of approximately
equal mass evenly distributed over the rough surface of the plate. For
each product, three plates were prepared and left to dry at room tem-
perature in the dark for 15–30 min before exposure, in order to facil-
itate the formation of a standard stabilized sunscreen film. After this
period, the plates were placed in the light path of the transmittance
analyzer. Then the measure of UV transmittance was carried out from
290 to 400 nm on 5 different sites of each plate. The blank was prepared
using a plate covered with 32.5 mg of glycerin. This substrate allows to
have a reference spectrum with a transmission close to 100% due to its
non-fluorescent and UV transparency.
Moreover, Values of in vitro SPF, UVA-PF and Critical Wavelength
were calculated according to Eq. (3), Eq. (4) and Eq. (5) [65] respec-
tively using SPF Calculator Software (SPF Calculator Software (version
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where E(λ) is the erythema action spectrum, I (λ) is the spectral irra-
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where P(λ) is the persistent pigment darkening (PPD) action spectrum.
C is the coefficient of adjustment. A(λ) is the mean monochromatic
absorbance of the test product layer after UV exposure.
The wavelength at which the summed absorbance reaches 90% of
total absorbance is defined as the critical wavelength. Therefore (Tλ)
were converted into absorbance values A(λ) following Eq. (5) and final
Critical Wavelength is:




where A(λ): monochromatic absorbance calculated from transmittance
at wavelength λ
3.3.3. Antifungal activity
3.3.3.1. Antidermatophyte activity. Microorganisms. The dermatophytes
used were Epidermophyton floccosum var. floccosum (Netherlands) CBS
358.93 strain; Trichophyton tonsurans (Netherlands) CBS 483.76 strain;
Trichophyton mentagrophytes (Netherlands) CBS 160.66 strain;
Microsporum canis (Iran) CBS 131110 strain; and Microsporum gypseum
(Iran) CBS 130948 strain. All dermatophytes were maintained at 4 °C as
agar slants on Sabouraud dextrose agar (SDA; Sigma-Aldrich SRL,
Milano, Italy).
Culture. In vitro antifungal activity against five dermatophytes was
evaluated using plate growth rate method. Each compound was dis-
solved in DMSO. Suitable solution adjusted to 0.1% was added to the
sterile culture medium (SDA) at 45 °C. The final concentration of the
medium was 100 µg·mL−1. The mixture was homogenized and trans-
ferred to a sterile Petri dish to solidify. Inoculums were previously
obtained by transplanting mycelium disks cut from the periphery of a
single mother cultures, incubated on thin sheets of cellophane deli-
cately extended on the agar plates and placed at 26 °C until the ap-
pearance of some characters that show how the fungus grew. According
to the poisoned-food technique [66], inoculums were then transferred
to analyzed Petri dish and incubated under growth conditions. The
mixed medium (SDA + DMSO) without sample was used as the blank
control. Antifungal activity was determined by measuring the diameter
of the inhibition zone for seven days. Percentages of growth inhibition
were calculated by comparing mean value of diameters of the mycelia
in test plates with that of untreated control plates following the Eq. (6).
The percent inhibition of growth was determined as the average of
three different experiments.
=I [(C T)/C]·100%. (6)
where I is the growth inhibition rate (%), C is the extended diameter of
the circle mycelium of the control (mm), and T is the extended diameter
of the circle during testing (mm).
3.3.3.2. Anti-Candida albicans activity. Stock solutions were prepared
by dissolving the compounds and Fluconazole in DMSO at a
concentration of 12.80 mg/mL. Minimal inhibitory concentration
(MIC) of the synthesized agents was performed by broth
microdilution method according to the Clinical and Laboratory
Standards Institute/National Committee for Clinical Laboratory
Standards (CLSI/NCCLS) Approved Standard M27-A3, 2008 [NCCLS].
RPMI 1640 was buffered with 0.165 M MOPS, solution was agitated
and brought to pH 6.9 with a 1 N NaOH solution. The solution was
filtered with 0.45 μm sterilized filter and stocked in fridge. Just before
setting up the assay, further dilute of stock solutions was dilute in 1:10
RPMI supplemented with Tween 80 (used as blank). Dilutions, 11
increasing concentrations, ranging from 0.25 to 128 µg·mL−1 of the
compounds, were prepared in 96-well plates. The inoculum size was
about 2.5 × 103 cells·mL−1. The plates were incubated at 30 °C for
24–48 h.
3.3.4. Antiproliferative activity
Cell lines. Human cervical carcinoma (HeLa), human CD4+T-lym-
phoblast (CEM) and human melanoma cells (SK-Mel 5) cells were ob-
tained from ATCC (Middlesex, UK). Human pancreatic carcinoma (Mia-
Paca 2) cells were kindly provided by Prof. Anna Karlsson (Karolinska
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Institute, Stockholm, Sweden). All cell lines were grown in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA), supple-
mented with 10% fetal bovine serum (FBS, Gibso), 0.01 M Hepes
(Gibco) and 1 mM sodium pyruvate (Gibco) in a humidified 5% CO2
incubator at 37 °C.
Cell proliferation. Suspension of CEM cells were seeded in 96-well
microtiter plates at 60,000 cells/well in the presence of different con-
centrations of the compounds. The cells were allowed to proliferate for
48 h or 72 h, respectively, and then counted in a Coulter counter. The
50% inhibitory concentration (IC50) was defined as the compound
concentration required to reduce cell proliferation by 50%. HeLa and
Mia-Paca2 cells were seeded in 96-well plates at 15,000 cells/well in
the presence of different concentrations of the compounds. After 4 days
of incubation, the cells were trypsinized and counted in a Coulter
counter).
IC50 Determination. The compounds were dissolved in DMSO at
20 mM (stock solution) and kept in the refrigerator until use. Then,
compound dilutions were made in cell culture medium, and serial
compound concentrations were tested starting at 100 μM as the highest
concentration. The DMSO concentration, present at the highest com-
pound concentration was 0.5% that is at a concentration that did not
affect the tumour cell proliferation. The IC50 values were calculated
using Eq. (7).
C1 [50 N1%/N2% N1%] (C1 C2) (7)
wherein C1 is the compound concentration that inhibits cell prolifera-
tion more than 50%; C2 is the compound concentration that inhibits
cell proliferation less than 50%; N1% represents the cell number (in
percent of control in the absence of compound) obtained in the pre-
sence of C1 and N2% represents the cell number (in percent of control
in the absence of compound) obtained in the presence of C2.
3.3.5. HERG expressed in HEK
Cell line. Electrophysiology study was performed using HEK293 cells
stably transfected with hERG cDNA.
Reagents and solutions. Test substances were formulated in 0.1%
DMSO. Stock solutions were diluted in extracellular solution plus 0.05%
Pluronic F-68 (Sigma), to final perfusion concentrations, which were
0.1, 1 and 10 µM. In positive control group, 0.003–0.03–0.3 µM E-4031
(Tocris) was assessed as a test compound. The mM composition of the
extracellular solution was: NaCl, KCl, CaCl2, MgCl2, D-glucose, N-(2-
hydroxyethyl)piperazine-N’-2-(ethanesulfonic acid) (HEPES), pH 7.4
with 1 M NaOH (137:4:1.8:1:10:10 respectively). The intracellular so-
lution composition was (in mM): KCl, MgCl2, Ethylene glycol-bis(ß-
aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA), MgATP, HEPES,
pH 7.2 with 1 M KOH (130:1:5:5:10 respectively). The intracellular
solution was filtered through a 0.2 µm polycarbonate membrane filter
upon formulation. All reagents were purchased from Sigma-Aldrich.
Voltage protocol. The voltage protocol used to evaluate the effect of
test substances on hERG channel current was as follows: step from
−80 mV to –50 mV for 200 ms, +20 mV for 4.8 s, step to −50 mV for
5 s then step to the holding potential of −80 mV. The step from
−80 mV to the test command (+20 mV) results in an outward current
(i.e. current flows out of the cell) and the step from the test command
(+20 mV) to −50 mV results in the tail current. The pulse pattern was
repeated continuously at 15 sec intervals from a holding potential of
−80 mV.
The voltage protocol was run and recorded continuously during the
experiment. The stability of recording was assessed through initial wash
with extracellular solution alone. The vehicle was then applied for
3 min followed by the test substance. The test substance was applied in
triplicate to ensure adequate mixing. The standard combined exposure
time was 5 min. Each test substance was tested in at least two cells for
every concentration. All experiments were performed at room tem-
perature.
Data analysis. Data acquisition and analyses were performed using
the QPatch Assay software. The average of current amplitude values
recorded from 4 sequential voltage pulses were used to calculate for
each cell the effect of the test substance by calculating the residual
current (% control) compared with vehicle pre–treatment and the % of
inhibition (Eq. (8)).
The normalized data were plotted against the concentration of
compound. The –Log of concentrations of compounds required to de-
crease current by 50% (pIC50) were determined by fitting the data to a
Hillequation with n ≥ 2
= + =I/I 1/[1 ([C]/IC50) ], with pIC logIC0 nH 50 50 (8)
where I0 and I are the current amplitudes measured in the absence and
presence of test compound, respectively, [C] is the concentration of
compound in the external solution and nH is the Hill coefficient.
3.4. Study of photostability
Each UV-filter incorporated in an oil-in-water (O/W) emulsion were
spread on PMMA plate and irradiated with a solar simulator applying
different UVA-dose equivalent to an effective erythema radiant ex-
posure of 120 kJ/m2. The spectral transmittance of thin film of sunsc-
reen was measured before and after sunlight exposure from 290 to
400 nm. The residual percentage of SPF in vitro (% SPFeff.) and UVA-PF
(% UVA-PFeff.)) were calculated according to Eqs. (9) and (10) re-
spectively. In fact, a filter is considered photostable if % SPFeff. and %
UVA-PFeff. are more than or equal to 80.
= ×in vitro in vitro%SPF . SPF / SPF 100eeff after befor (9)
= ×%UVA PF UVA PF /UVA PF 100eff after before (10)
4. Conclusions
The development of ltifunctional compounds is of great importance
due to the correlation of biological networks. For this purpose, a series
of benzothiazole derivatives was synthesized and investigated for its in
vitro sunscreen UV-filter capacity, antioxidant, antifungal and anti-
proliferative activities. Regarding sunscreen UV-filter capacity, com-
pounds 4g, 4h, 4k, 11d, 11g, 11o and 11r could be considered as
broad-spectrum and also UVA-filter compounds since their
λc ≥ 370 nm and the UVA-PF value of each compound was greater
than 1/3 of its SPF value. While compounds 4d and 4j were potential
compounds for UVB protection. In addition, photostability studies
showed that all synthesized compounds are photostable especially 11e
with a degradation rate less than 2%. In terms of antioxidant activity,
compounds of classes F and H, characterized respectively by the pre-
sence of two hydroxyl groups in positions 3,4 and 2,5 of the 2-aryl ring
showed good antioxidant profile. According to antifungal activity,
compound 4h showed the highest activity against all five dermato-
phytes, in particular against Microsporum gypseum, Trichophyton ton-
surans and Epidermophyton floccosum. Moreover, significant activity was
also observed for compounds 4f and 4g against Microsporum gypseum
and Epidermophyton floccosum. With regard to the antiproliferative ac-
tivity, compounds 4g and 4k are the potential compounds against CEM
and SK-Mel 5 tumor cells, however, 4k showed the best activity: it was
respectively 6-fold more selective for CEM and 25-fold more selective
toward SK-Mel 5 cells. Furthermore, compounds 4e, 11n and 11o were
respectively 15, 18 and 5 fold more selective toward Mia-Paca-2 cells.
Considering that inhibition of HERG channels reduces proliferation and
impairs invasiveness in several cancer cell types, hERG channels ex-
pressed in HEK cells can be target receptor for compounds with good
anticancer activity. In these regards we may conclude that compound
4g could be the potential candidate for blocking hERG potassium
channels.
Taking into account all the biological evaluation, 4g and 4k could
be potential compounds for the design of multifunctional drugs because
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of their various biological activities. In addition, the benzothiazole
derivatives could have a possible application as drugs for the treatment
of neoplastic diseases including childhood leukemia, pancreatic cancer
and melanoma. All together the data obtained have highlighted inter-
esting activities sufficient to propose this scaffold as potential useful-
ness in the design of multifunctional compounds. Finally, the activity
on Mia-Paca-2, SK-Mel5 and CEM cells paralleled by hERG channel
inhibition warrant further investigation because of the importance in
antitumor therapy.
Declaration of Competing Interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper.
Acknowledgment
This work was supported by University of Ferrara (Grant FAR 2017
to SM and SV) and the Ministry of Education University and Research of
Italy (grant PRIN 2017E84AA4_002 to SM) and Ambrosialab srl
(Ferrara, Italy); the scholarship to ES was kindly supported by APTUIT
(Verona, Italy). We thank Selena Nola for doing the hERG study.
Appendix A. Supplementary material
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bioorg.2020.103960.
References
[1] Y. Fang, H. Zhou, Q. Gu, J. Xu, Synthesis and evaluation of tetrahydroisoquinoline-
benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer's
disease, Eur. J. Med. Chem. 167 (2019) 133–145.
[2] A. Baldisserotto, M. Demurtas, I. Lampronti, D. Moi, G. Balboni, S. Vertuani,
S. Manfredini, V. Onnis, Benzofuran hydrazones as potential scaffold in the devel-
opment of multifunctional drugs: Synthesis and evaluation of antioxidant, photo-
protective and antiproliferative activity, Eur. J. Med. Chem. 156 (2018) 118–125.
[3] F. Afaq, V.M. Adhami, H. Mukhtar, Photochemoprevention of ultraviolet B sig-
naling and photocarcinogenesis, Mutat. Res. 571 (2005) 153–173.
[4] G.T. Wondrak, M.K. Jacobson, E.L. Jacobson, Endogenous UVA photosensitizers:
mediators of skin photodamage and novel targets for skin photoprotection,
Photochem. Photobiol. Sci. 5 (2006) 215–237.
[5] N. Saewan, A. Jimtaisong, Photoprotection of natural flavonoids, J. Appl. Pharama.
Sci. 3 (2013) 129–141.
[6] S. Courdavault, C. Baudouin, M. Charveron, B. Canguilhem, A. Favier, J. Cadet,
T. Doukia, Repair of the three main types of bipyrimidine DNA photoproducts in
human keratinocytes exposed to UVB and UVA radiations, DNA Repair. 4 (2005)
836–844.
[7] D. Mitchell, A. Fernandez, The photobiology of melanocytes modulates the impact
of UVA on sunlight-induced melanoma, Photochem. Photobiol. Sci. 11 (2012)
69–73.
[8] M.E. Inal, A. Kahramant, T. Kkent, Beneficial effects of quercetin on oxidative stress
induced by ultraviolet A, Clin. Exp. Dermatol. 26 (2001) 536–539.
[9] M. Wlaschek, I. Tantcheva-Poor, L. Naderi, W. Ma, L.A. Schneider, Z. Razi-Wolf,
J. Schuller, K. Scharffetter-Kochanek, Solar UV irradiation and dermal photoaging,
J. Photochem. Photobiol. B. 63 (2001) 41–51.
[10] Hossam El-Din M. Omar. Mycotoxins-Induced Oxidative Stress and Disease, Chapter
3, http://dx.doi.org/10.5772/51806.
[11] L.A. Corcuera, S. Amézqueta, L. Arbillaga, A. Vettorazzi, S. Touriño, J.L. Torres,
A. Lopéz de Cerain, A polyphenol-enriched cocoa extract reduces free radicals
produced by mycotoxins, Food Chem. Toxicol. 50 (2012) 989–995.
[12] A. Bino, A. Baldisserotto, E. Scalambra, V. Dissette, D.E. Vedaldi, A. Salvador,
E. Durini, S. Manfredini, S. Vertuani, Design, synthesis and biological evaluation of
novel hydroxy-phenyl-1H-benzimidazoles as radical scavengers and UV-protective
agents, J. Enzyme Inhib. Med. Chem. 32 (2017) 527–537.
[13] S. Kumar, D.S. Rathore, G. Garg, K. Khatri, R. Saxena, S.K. Sahu, Synthesis and
evaluation of some benzothiazole derivatives as antidiabetic agents, Int. J. Pharm.
Pharm. Sci. 9 (2017) 60–68.
[14] R.S. Keri, C. Quintanova, S.M. Marques, A.R. Esteves, S.M. Cardoso, M.A. Santos,
Design, synthesis and neuroprotective evaluation of novel tacrine–benzothiazole
hybrids as multi-targeted compounds against Alzheimer’s disease, Bioorg. Med.
Chem. 21 (2013) 4559–4569.
[15] N. Gupta, N. Ajmera, R. Gautam, D. Sharma, Gauatam, Novel synthesis and biolo-
gical activity study of pyrimido [2,1-b] benzothiazoles, Ind. J. Chem. 48B (2009)
853–858.
[16] R.M. Kumbhare, V.N. Ingle, Synthesis of novel benzothiozole and benzisoxazole
functionalized unsymmetrical alkanes and study of their antimicrobial activity, Ind.
J. Chem. 48B (2009) 996–1000.
[17] Y. Murthi, D. Pathak, Synthesis and Antimicrobial screening of Substituted 2-
Mercaptobenzothiazoles, J. Pharm. Res. 7 (2008) 153–155.
[18] M. Maharan, S. William, F. Ramzy, A. Sembel, Synthesis and in vitro Evaluation of
new benzothiazolederivaties as schistosomicidal agents, Molecules 12 (2007)
622–633.
[19] B. Rajeeva, N. Srinivasulu, S. Shantakumar, Synthesis and Antimicrobial activity of
some new 2-substituted benzothiazole derivatives, E-J. Chem. 6 (2009) 775–779.
[20] S. Agarwal, D.K. Agarwal, N. Gautam, K. Agarwal, D.C. Gautam, Synthesis and in
vitro antimicrobial evaluation of benzothiazole incorporated thiazolidin-4-ones
derivatives, J. Korean Chem. Soc. 58 (2014) 33–38.
[21] M.K. Singh, R. Tilak, G. Nath, S.K. Awasthi, A. Agarwal, Design, synthesis and
antimicrobial activity of novel benzothiazole analogs, Eur. J. Med. Chem. 63 (2013)
635–644.
[22] S.K. Rangappa, M.R. Patil, S.A. Patil, S. Budagumpi, A comprehensive review in
curren developments of benzothiazolebased molecules in medicinal chemistry, E. J.
Med. Chem. 89 (2015) 207e251.
[23] J.C. Chen, L. Qian, Y. Shen, L.M. Chen, K.C. Zheng, A QSAR study and molecular
design of benzothiazole derivatives as potent anticancer agents, Sci. China Ser. B-
Chem. 51 (2008) 111–119.
[24] A.L. Loaiza-Pérez, V. Trapani, C. Hose, S.S. Singh, J. Trepel, M.F.G. Stevens, T.D.
Bradshaw, E.A. Sausville, The aryl hydrocarbon receptor mediates sensitivity of
MCF-7 breast cancer cells to the antitumor agent 2-(4-amino-3-methylphenyl)ben-
zothiazole, Mol. Pharmacol. 61 (2002) 13–19.
[25] V. Trapani, V. Patel, H.P. Ciolino, G.C. Yeh, C. Hose, J.B. Trepel, M.F.G. Stevens,
E.A. Sausville, A.L. Loaiza-Pérez, DNA damage and cell cycle arrest induced by 2-(4-
amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated
in aryl hydrocarbon receptor deficient MCF-7 cells, Br. J. Cancer 88 (2003)
599–605.
[26] R. Caputo, M.L. Calabro, N. Micale, A.D. Schimmer, M. Ali, M. Zappala, S. Grasso,
Synthesis of benzothiazole derivatives and their biological evaluation as anticancer
agents, Med. Chem. Res. 21 (2012) 2644–2651.
[27] M. Yoshida, I. Hayakawa, N. Hayashi, T. Agatsuma, Y. Oda, F. Tanzawa, S. Iwasaki,
K. Koyama, H. Furukawa, S. Kurakatad, Y. Sugano, Synthesis and biological eva-
luation of benzothiazole derivatives as potent antitumor agents, Bioorg. Med.
Chem. Lett. 15 (2005) 3328–3332.
[28] E.L. Stone, F. Citossi, R. Singh, B. Kaur, M. Gaskell, P.B. Farmer, A. Monks, C. Hose,
M.F. Stevens, C.O. Leong, M. Stocks, B. Kellam, M. Marlow, T.D. Bradshaw,
Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks cor-
relate with activity; synthesis of 5F203 hydrogels for local delivery, Bioorg. Med.
Chem. 23 (2015) 6891–6899.
[29] J. Ma, G. Bao, L. Wang, W. Li, B. Xu, B. Du, J. Lv, X. Zhai, P. Gong, Design,
synthesis, biological evaluation and preliminary mechanism study of novel ben-
zothiazole derivatives bearing indole-based moiety as potent antitumor agents, Eur.
J. Med. Chem. 96 (2015) 173–186.
[30] M.F.G. Stevens, C.J. McCall, P. Lelieveld, P. Alexander, A. Richter, D.E. Davies,
Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-
phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological
properties with genistein and quercetin, J. Med. Chem. 37 (1994) 1689–1695.
[31] A.A. Mohammed, D. Loganathan, C.M. Charu, S. Sumit, Synthesis and biological
evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring
system, Acta Pharm. 63 (2013) 19–30.
[32] K. Vishal, S. Saurabh, H. Asif, Synthesis and in vivo Anti-inflammatory and
Analgesic activities of Oxadiazoles clubbed with Benzothiazole nucleus, Int. Curr.
Pharmaceut. J. 4 (2015) 457–461.
[33] N. Siddiqui, A. Rana, S.A. Khan, M.A. Bhat, S.E. Haque, Synthesis of benzothiazole
semicarbazones as novel anticonvulsants—The role of hydrophobic domain, Bioorg.
Med. Chem. Lett. 17 (2007) 4178–4182.
[34] D.C. Liu, X.Q. Deng, S.B. Wang, Z.S. Quan, Synthesis and anticonvulsant activity
evaluation of 7-alkoxy[1,2,4]triazolo[3,4-b]benzothiazol-3(2H)-ones, Arch. Pharm.
Chem. Life Sci. 347 (2014) 268–275.
[35] M.Z. Hassan, S.A. Khan, M. Amir, Design, synthesis and evaluation of N-(substituted
benzothiazol-2-yl)amides as anticonvulsant and neuroprotective, Eur. J. Med.
Chem. 58 (2012) 206–213.
[36] V.G. Ugale, H.M. Patel, S.G. Wadodkar, S.B. Bari, A.A. Shirkhedkar, S.J. Surana,
Quinazolino-benzothiazoles: Fused pharmacophores as anticonvulsant agents, Eur.
J. Med. Chem. 53 (2012) 107–113.
[37] R.I. Cuevas-Hernández, J. Correa-Basurto, C.A. Flores-Sandoval I.I. Padilla-
Martínez, B. Nogueda-Torres, M. de L. Villa-Tanaca, F. Tamay-Cach, J.J. Nolasco-
Fidencio, J.G. Trujillo-Ferrara, Fluorine-containing benzothiazole as a novel try-
panocidal agent: design, in silico study, synthesis and activity evaluation, Med.
Chem. Res. 25 (2016) 211–224.
[38] B. Chi, C. Jill, P. David, J. Song, W. Choy, P. Lambert, D. Gagne, Discovery of
benzothiazole derivatives as efficatious and enterocyte-specific MTP inhibitors,
Bioorg. Med. Chem. Lett. 19 (2009) 1416–1420.
[39] C.A. Mathis, Y. Wang, D.P. Holt, G.-F. Huang, M.L. Debnath, W.E. Klunk, Synthesis
and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid ima-
ging agents, J. Med. Chem. 46 (2003) 2740–2754.
[40] P.S. Yadav, D. Devprakash, G.P. Senthilkumar, Benzothiazole: different methods of
synthesis and diverse biological activities, Int. J. Pharm. Sci. Drug. Res. 3
(2011) 1–7.
[41] M.R. Chedekel, P. PohAgin, R.M. Sayre, Photochemistry of pheomelanin: action
spectrum for superoxide production, Photochem. Photobiol. 31 (1980) 553–555.
[42] K. Herrmann, Occurrence and content of hydroxycinnamic and hydroxybenzoic
E.N. Djuidje, et al. Bioorganic Chemistry 101 (2020) 103960
14
acid compounds in foods, Crit. Rev. Food Sci. Nutr. 28 (1989) 315–347.
[43] Z.A. Velkov, M.K. Kolev, A.V. Tadjer, Modeling and statistical analysis of DPPH
scavenging activity of phenolics, Collect. Czech. Chem. Commun. 72 (2007)
1461–1471.
[44] A.A. Weekes, M. Bagley, A.D. Westwell, An efficient synthetic route to biologically
relevant 2-phenylbenzothiazoles substituted on the benzothiazole ring, Tetrahedron
67 (2011) 7743–7747.
[45] M. Hiroharu, O. Nobuhiro, M. Masahiko, S. Hiroshi, M. Katsuhito, M. Noriaki,
T. Keiichiro, K. Nobuaki, A. Toshio, T. Yasuhisa, Y. Keiichi, K. Toshio,
Antirheumatic agents: novel methotrexate derivatives bearing a benzoxazine or
benzothiazine moiety, J. Med. Chem. 40 (1997) 105–111.
[46] J. Dey, S.K. Dogra, Electronic absorption and fluorescence spectra of 2-phenyl-
substituted benzothiazoles: study of excited-state proton transfer reactions, Can. J.
Chem. 69 (1991) 1539–1547.
[47] B.L. Diffey, J. Robson, A new substrate to measure sunscreen protection factors
throughout the ultraviolet spectrum, J. Soc. Cosmet. Chem. 40 (1989) 127–133.
[48] J.D. Fourneron, F. Faraud, A. Fauneron, Sur la mesure in vitro de la protection
solaire de crèmes cosmétiques, C. R. Acad. Sci. II, Paris 2 (1999) 421–427.
[49] M. Pissavini, L. Ferrero, V. Alaro, U. Heinrich, H. Tronnier, D. Kockott, D. Lutz,
V. Tournier, M. Zambonin, M. Meloni, Determination of the in vitro SPF, Cosmet.
Toiletries, Oak Park. 118 (2003) 63–72.
[50] A. Dimitrovska Cvetkovska, S. Manfredini, P. Ziosi, S. Molesini, V. Dissette, I. Magri,
C. Scapoli, A. Carrieri, E. Durini, S. Vertuani, Factors affecting SPF in vitro mea-
surement and correlation with in vivo results, Int. J. Cosmet. Sci. 39 (2017)
310–319.
[51] SPF Calculator Software (version 2.1), Shimadzu, Milan (Italy).
[52] US Food and Drug Administration, 21 CFR Parts 347 and 352, Sunscreen Drug
Products for Over-the-Counter Human Use; Proposed Amendment of Final
Monograph, Silver Spring, MD (USA), 2007, https://www.fda.gov/ OHRMS/
DOCKETS/98fr/cd031.pdf (accessed April 25, 2017).
[53] D. Garoli, M.G. Pelizzo, B. Bernardini, P. Nicolosi, M. Alaibac, Sunscreen tests:
Correspondence between in vitro data and values reported by the manufacturers, J.
Dermatol. Sci. 52 (2008) 193–204.
[54] A.M. Farrelly, S. Ro, B.P. Callaghan, M.A. Khoyi, N. Fleming, B. Horowitz,
K.M. Sanders, K.D. Keef, Expression and function of KCNH2 (HERG) in the human
jejunum, Am. J. Physiol. Gastrointest. Liver Physiol. 284 (2003) 883–895.
[55] J.E. Brayden, M.T. Nelson, Regulation of arterial tone by activation of calcium-
dependent potassium channels, Science 256 (1992) 532–535.
[56] M.E. Laniado, S.P. Fraser, M.B. Djamgoz, Voltagegated K (+) channel activity in
human prostate cancer cell lines of markedly different metastatic potential:
Distinguishing characteristics of PC-3 and LNCaP cells, Prostate 46 (2001) 262–274.
[57] K. Preussat, C. Beetz, M. Schrey, R. Kraft, S. Wolfl, R. Kalff, S. Patt, Expression of
voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas, Neurosci.
Lett. 346 (2003) 33–36.
[58] X.T. Wang, Y. Nagaba, H.S. Cross, F. Wrba, L. Zhang, S.E. Guggino, The mRNA of L-
type calcium channel elevated in colon cancer: Protein distribution in normal and
cancerous colon, Am. J. Pathol. 157 (2000) 1549–1562.
[59] A. Cherubini, G.L. Taddei, O. Crociani, M. Paglierani, A.M. Buccoliero, L. Fontana,
I. Noci, P. Borri, E. Borrani, M. Giachi, A. Becchetti, B. Rosati, E. Wanke,
M. Olivotto, A. Arcangeli, HERG potassium channels are more frequently expressed
in human endometrial cancer as compared to non-cancerous endometrium, Br. J.
Cancer 83 (2000) 1722–1729.
[60] A.P. Hegle, D.D. Marble, G.F. Wilson, A voltage-driven switch for ion independent
signaling by ether-à-go-go K+ channels, Proc. Natl. Acad. Sci. USA 103 (2006)
2886–2891.
[61] E. Afrasiabi, M. Hietamäki, T. Viitanen, P. Sukumaran, N. Bergelin, K. Törnquist,
Expression and significance of HERG (KCNH2) potassium channels in the regulation
of MDA-MB-435 S melanoma cell proliferation and migration, Cell Signal. 22
(2010) 57–64.
[62] J.J. Babcock, M. Li, hERG channel function: beyond long QT, Acta Pharmacol. Sin.
34 (2013) 329–335.
[63] M. Wang, J. Li, M. Rangarajan, Y. Shao, E.J. La Voie, T.-C. Huang, C.-T. Ho,
Antioxidative phenolic compound from sage (salvia officinalis), J. Agric. Food
Chem. 46 (1998) 4868–4873.
[64] I.F.F. Benzie, J.J. Strain, The ferric reducing ability of plasma as a measure of an-
tioxidant power: the FRAP assay, Anal. Biochem. 239 (1996) 70–76.
[65] S.G. Rezende, J.G. Dourado, F.M.A. Lino, D.C. Vinhal, E.C. Silva, E.S. Gil, Methods
used in evaluation of the sun protection factor of sunscreens. REF-ISSN1808-0804,
revista electronic de farmàcia XI (2014) 37–54.
[66] C. Romagnoli, A. Baldisserotto, C.B. Vicentini, D. Mares, E. Andreotti, S. Vertuani,
S. Manfredini, Antidermatophytic action of resorcinol derivatives: ultrastructural
evidence of the activity of phenylethyl resorcinol against Microsporum gypseum,
Molecules. 21 (2016) 1306.
E.N. Djuidje, et al. Bioorganic Chemistry 101 (2020) 103960
15
